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1.ABSTRACT 
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The intracellular chloride channel 1 (CLIC1) is a peculiar metamorphic protein, belonging to a 
still partially unexplored family of chloride channels, that shuttles between a cytoplasmic and 
a transmembrane form, the latter able to form a chloride selective ion channel. Different 
factors regulate this membrane insertion, in particular an increase in the oxidative level and a 
modification in the pH. CLIC1 has been found to be overexpressed in different tumors, 
among the others in Glioblastoma Multiforme (GBM). GBM is the most lethal, aggressive and 
diffuse brain tumor. One of the clinical challenges of GBM treatment is to hit selectively its 
cancer stem cells (CSCs) that are responsible for tumor origin, progression and recurrence. 
CLIC1 protein, in its transmembrane form, has a pivotal role in the tumorigenic potential, 
proliferation and self-renewal of CSCs isolated from grade IV human GBM. CLIC1 could 
represent a suitable pharmacological target as the protein, physiologically located in the 
cytoplasm, is highly expressed in the plasma membrane only of glioblastoma CSCs enriched 
cultures. In a work published last year from our laboratory we have shown that blocking 
CLIC1 ionic current impairs specifically proliferation of CSCs and tumor development; 
moreover, we demonstrated a partial but significant arrest of cells in G1 phase after CLIC1 
functional inhibition. Our experiments further demonstrate the great potential of CLIC1 as a 
pharmaceutical target since the functional expression of CLIC1 protein as a chloride ion 
channel occurs selectively in CSCs compared to Mesenchimal Stem Cells. My thesis work 
has been concentrated in the direction of uncovering the mechanism that regulates the 
protein expression in the plasma membrane of GBM cancer stem cells. My results have 
shown that CLIC1 membrane ionic current is differently tuned during the cell division process 
and its activity is fundamental for the progression of the cell cycle since the inhibition of 
CLIC1 transmembrane ionic flow causes a drastic reduction in the transition between G1 and 
S phase. Electrophysiology experiments showed that the chloride conductance mediated by 
CLIC1 in CSCs is increased at specific time points after the release from G1 synchronization 
of the cells. This tuning is regulated by an increase in the internal pH of CSCs that occurs 
during the progression of G1 phase of the cell cycle. Moreover, the last experiment set that I 
performed showed a regulation of CLIC1 chloride conductance during G1 phase also by 
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Reactive Oxygen Species (ROS) production by NADPH oxidase. Since both acute and 
chronic inhibition of CLIC1 channel activity with the specific inhibitor IAA94 leads to alteration 
in both internal pH and ROS levels I speculate a feed-forward mechanisms that links all 
these three elements that work synchronously to allow the progression through the cell cycle.  
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2.INTRODUCTION 
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2.1 Chloride channels and cancer 
Over the last two decades an important role for ion channels in tumor developing and growth 
has been defined, so that they are currently included among the novel targets for cancer 
therapy. Channel dysfunctions may have a strong impact on cell physiology and signaling 
and it became clear that an abnormal triggering of ion channels activity could be important to 
support the high rate of proliferation of tumor cells. On behalf of this, ion channels expression 
is often altered in tumor cells; during the change from a physiological conditions  towards 
neoplastic state a series of genetic alterations occurs, which may also affect the expression 
of ion channels or may cause a change in ion channel activity [8]. 
In the last years it has been confirmed the implication of ionic permeabilities  in many 
aspects of cancer pathology, including uncontrolled growth, decreased apoptosis, 
disorganized angiogenesis, aggressive migration, invasion and metastasis [9]. A great 
number of studies in this field focused on the role of potassium channels but, with the flow of 
time, chloride channels gain more significance in this regulation [10]. 
Chloride channels are expressed ubiquitously and they reside both in the plasma membrane 
and in intracellular organelles. They have many different functions as the regulation of 
electrical excitability, transepithelial fluid transport, ion homeostasis, pH levels or cell volume 
regulation, the latter particularly important in cancer. Lately, it has been demonstrated that 
these channels have also a role in the regulation of the cell cycle progression, probably as a 
key factor for the progression from G1 to S phase. The different families of chloride channels 
display heterogeneous characteristics in the control of their activity. Specifically they can be 
voltage-activated, calcium-activated, ligand-activated, volume-activated or, in the case of 
cystic fibrosis transmembrane conductance regulator (CFTR), activated by cyclic AMP-
dependent phosphorylation [11]. 
The intracellular chloride concentration is central to the activity of channels and transporters. 
As an example, the polarity of GABA responses depends upon it. In the immature brain, 
where the internal chloride concentration is high, the activation of GABA receptors promote a 
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depolarization. In contrast, in the adult brain, the amount of chloride inside the cell is lower, 
with consequent inhibitory action of GABAAergic currents [12]. 
Moreover, in the last years it has been shown that the cells use changes in intracellular 
chloride concentration to modulate many physiological functions, for example the regulation 
of mRNA expression of ion channels [13, 14], the activation of signaling molecules of the 
apoptotic pathway [14] or the release of prostaglandin [15]. 
Chloride currents have a role in the proliferation of many cell types like microglia, glioma 
cells, cells from neuroblastoma and endothelial cells [16-19]. In addition, as for K+ channels, 
it has been observed a cell cycle-dependent expression of Cl- channels. For example, ClC-5 
expression in myeloid cells was high during S and G2/M and low in G0/G1[20]. In 
lymphocytes, chloride permeability also varied with the cell cycle, being low in G0 and S 
phase and high in G1/S [21]. The cell cycle-dependent expression of a glioma-specific 
chloride channel was linked to cytoskeletal rearrangements associated with cell division and 
cell swelling [22]. It is likely that, during proliferation, these channels balance transmembrane 
movement of ions and substrates and provide a mechanism for regulatory cell volume 
decrease (RVD) during cell cycling [8].  
In light of these observations we can speculate that the internal chloride concentration could 
play an important role also in cancer cells, acting like a messenger to activate downstream 
pathways.  
The literature offers us many examples of how chloride channels are involved in tumors 
development and progression. Members of the different families of chloride channels have 
been reported to have an active role in various tumors’ progression. As an example, voltage-
gated chloride channels, in particular CLC-3, CLC-2 and CLC-5 are involved in the regulation 
of cell volume needed for cells migration and invasion in glioblastoma [23]. CLC-3 in 
particular has a role also in other tumors like prostate cancer or nasopharyngeal carcinoma 
[24, 25].  
In the last years, members of the intracellular chloride channels (CLICs) family, in particular 
CLCI1 and CLIC4, gained a more important role in tumors progression and development. As 
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the two channels have different patterns of expression in different tissues they also have 
different levels of expression in different tumors. The peculiarity of the channels belonging to 
this family, compared to “classical” membrane-resident chloride channels, is that their 
translocation and functional membrane insertion could be modulated in response to different 
stimuli like perturbation of cell homeostasis, making them a particular and very interesting 
pharmacological target [26].   
 
2.2 Chloride intracellular channel 1 (CLIC1) 
Among all the well characterized chloride channels, the chloride intracellular channel (CLIC) 
protein family has been the last discovered and still largely underexplored. These proteins 
are highly conserved in all vertebrates suggesting their involvement in basic biological 
functions. The first identified intracellular chloride channel, p64, was isolated from 
microsomes of bovine kidney and trachea and showed chloride selective channel function in 
lipid bilayers [27].  
As mentioned above, distinct from membrane resident ion channels, these proteins can exist 
both as cytoplasmic soluble proteins as well as integral membrane elements with ion channel 
activity. Membrane insertion occurs in response to different  stimuli from increases of 
cytoplasmic oxidation to pH changes [7, 28, 29]. 
CLIC1 and CLIC4 were the first CLIC proteins to be cloned and functionally studied [30, 31], 
and so far they remain the most characterized within the whole family. 
CLIC1 was first cloned in 1997 from a human monocytic cell line. Firstly identified on the 
nuclear membranes, it was then localized also on the plasma membranes [30, 32]. This 
channel is highly conserved among the vertebrates, it is ubiquitously expressed in the 
different tissues and it is overexpressed in different tumors [26, 28].  
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2.2.1 Structure and biophysical properties 
CLIC1 is a 241 amino acid protein with a 
molecular weight of 27 kDa. Being a 
metamorphic protein [33], it has different 
tertiary structures that correspond to the 
same primary sequence; it exists usually in a 
soluble form in the cytoplasm and 
nucleoplasm, but following different stimuli it 
undergoes major structural changes and 
inserts in lipid membranes where it acts as a 
chloride-selective ion channel [29, 34-36].  
The structure of the soluble form of CLIC1 has been determined in two crystal forms at 1.4-Å 
and 1.75-Å resolution by Harrop and colleagues in 2001. This structure indicates that it is a 
homolog of the member of the GST superfamily. The N-domain (residues 1–90) has a 
thioredoxin fold that consists of a four-stranded mixed β-sheet plus three α-helices, while the 
C-domain is all helical, closely resembling the Ω class GST (Figure 1). 
The N-domain has a well conserved glutaredoxin-like site for covalently interacting with GSH. 
Glutathione appears to be covalently attached to Cys24 via a disulfide bond, noncovalent 
binding of GSH to CLIC1 appears to be weak. In oxidizing conditions, glutathione detaches 
from its binding site and the N-terminal domain of the protein undergoes conformational 
rearrangements that expose hydrophobic regions that are able to interact with cellular 
membranes [37].  
The crystal structure of the transmembrane form still has to be resolved. It has been 
postulated one putative transmembrane helix to form the membrane-spanning region of the 
CLIC1 module; it shows the length and the hydrophobic features necessary to spam the 
Figure 1: Crystal structure of CLIC1 monomer[6] 
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plasma membrane. This region is localized between Cysteine 24 and Valine 46 and is 
located within the N-terminal domain.  
In the structure of the monomeric soluble form of CLIC1, this putative segments forms a α 
helix and a β strand within the glutaredoxin-like-N-domain. Thus, in the transition from the  
hydrophilic to the membrane binding protein a large scale structural rearrangement, that may 
involve the N-domain of CLIC1 and disrupt the glutathione-binding site, is likely to occur [4, 
7]. 
The structure of a dimeric, soluble, oxidized form of CLIC1 was resolved by Littler and 
colleagues in 2004 (Figure 2). In this form the glutaredoxine-like-N-domain has undergone a 
radical rearrangement to expose an extended hydrophobic surface, which forms the dimer 
interface. This transition, that is reversible on reducing conditions, is stabilized through the 
formation of an intramolecular disulfide bond between two originally distant cysteine 
residues, Cys-24 and Cys-59. This dimer is able to form, in artificial lipid bilayers, chloride ion 
channels similar to the native channel. The mutation of either one of the two cysteine 
residues results in the loss of channel activity [7].  
The mechanisms that allow CLIC1 membrane insertion still has to be fully elucidated. 
According to Littler model they suggest that the hydrophobic region exposed after the 
oxidation-dependent transition may represent the membrane docking interface. 
Goodchild and colleagues performed experiments to clarify this membrane insertion 
mechanism. They suggested that the dimerization process is not necessary for the insertion 
of the protein into membranes. They propose a model in which at first there is a docking of 
monomeric CLIC1 to the membrane internal side and successively cytoplasmic oxidation 
promotes the structural changes that allow the protein to cross the membrane and form a 
Figure 2: structure of the oxidized CLC1 dimer viewed along (left) and perpendicular (D) to the pseudo 2 -fold 
axis[7] 
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functional ion channel. They showed that both monomeric and dimeric forms are able to form 
functional ion channels in artificial membranes [6].  
It has been demonstrated that, once inserted in the membrane, the protein exposes its N-
terminus to the extracellular side, whereas the C-terminus remains on the intracellular side of 
the membrane [32].  
Despite the fact that is still not clear how many subunits participates to form the functionally 
active structure, once inserted in the membrane, CLIC1 is able to act as a selective chloride 
channel; different hypothesis propose the 
association of two or four subunits, until the 
formation of small oligomers of six or eight 
subunits, to constitute one single ion channel [6, 
28, 29, 32, 34, 35].   
Besides the oxidative level of the cytoplasm, as 
previously reported, the pH of the intracellular 
compartment plays a role in the regulation of 
CLIC1 membrane insertion. It has been demonstrated that in artificial lipid bilayers CLIC1 
channel activity is dependent on H+ ion concentration: it is minimal at pH 7 and it increases 
significantly with changes in the pH of the vesicles containing the protein (Figure 3)  [4]. 
Recently it has been shown that, in particular, two histidine residues are fundamental or this 
pH-dependency [38]. 
Electrophysiological experiments performed on CHO cells transfected with a plasmid to 
overexpress CLIC1 allowed to understand the biophysical features of the channel. In 
physiological conditions, when the cells are at membrane voltages higher than the chloride 
reversal potential, CLIC1 mediates an outward current that rectified at +40/+50 mV. A small 
inward current is recorded at potential lower than the chloride reversal potential [32].  
CLIC1 mediated current is completely and reversely blocked by the specific inhibitor IAA94 
(Indanyloxyacetic acid 94), while the aspecific inhibitor of chloride channels DIDS (4,4'-
Diisothiocyano-2,2'-stilbenedisulfonic acid) does not have an effect on CLIC1 conductance 
Figure 3: Effect on pH on CLIC1 activity in lipid 
bilayers[4] 
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[39]. A recent work published form our laboratory propose the antidiabetic drug metformin, 
that also has an antitumoral effect, as a selective blocker for CLIC1 channel activity [5].  
2.2.2 Role in the pathology  
Oxidation is one of the most important stimuli responsible for CLIC1 membrane colonization.  
Reactive Oxygen Species  (ROS)  may act as compounds that impair cell and protein 
function, but they may also act as second messengers in cellular processes that involve 
changes in the cellular redox state, including migration, differentiation, and cell replication. 
Indeed, many proteins have redox-sensitive motifs. Cell homeostatic mechanisms establish a 
balance between ROS production and their removal by antioxidant  systems. The 
overwhelming of antioxidant defenses by ROS generation results in a condition of oxidative 
stress. Several pathological conditions are characterized by changes in cellular redox state, 
in particular chronic inflammatory states, oncologic conditions [40] and degenerative process 
[41-43]. Concerning CLIC1 role in diseases, it has been observed an involvement of the 
membrane protein during tumor proliferation or in neurodegenerative processes [44-46]; 
these two pathological states share the common feature of an overproduction of ROS.  The 
hypothesis that CLIC1, in its channel form, could play a role in the pathophysiology of these 
conditions promotes the protein as a potential valid therapeutic target.  
Alzheimer’s diseases (AD) is characterized by an activation of the microglia induced by β 
amyloid (Aβ). Once the microglia is activated is highly proliferating and it produces a large 
amount of ROS due to the activity of membrane NADPH (Nicotinamide Adenine Dinucleotide 
Phosphate) oxidase. Our laboratory has shown that in microglia stimulated by Aβ, CLIC1 is 
over-expressed [44]. The blockade of CLIC1 functional expression limits the detrimental 
effects due to the over-activation of microglia cells, impairing the production of TNF-α, nitrites 
and ROS [45]. The hypothesis about the role of CLIC1 during ROS hyper-production is linked 
to the fact that NADPH oxidase function is strictly dependent on the membrane potential, 
since depolarized voltages limit its activity. Hence, CLIC1 could have a role as a “charge 
compensator” to maintain hyperpolarized membrane voltages and sustain NADPH oxidase 
activity. In this way, not only CLIC1 membrane translocation is promoted by an increase in 
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ROS production, but also ROS production is supported by the chloride current mediated by 
CLIC1 channel [45].  
Concerning CLIC1 and its expression in cancers, the protein levels are reportedly increased 
in human breast ductal carcinoma [47], gastric cancer [48], gallbladder metastasis [49], 
colorectal cancer [50], nasopharyngeal carcinoma [51], ovarian cancer [52], hepatocellular 
carcinoma [53] and high-grade gliomas [54]. All these reports propose CLIC1 as a tumor 
marker, sometimes detectable even in the plasma of patients and so very useful in the clinic. 
It is known that oxidative level oscillations in the intracellular compartment contributes to the 
regulation of cell cycle progression through the different phases [55] and that alterations in 
the oxidative basal level of the cells are typical conditions for many tumorigenic processes. It 
is not surprisingly so that the activity of CLIC1 channel, induced by the oxidation, is higher in 
hyper-proliferating tumor cells. Like activated microglia, cancer cells could also take 
advantage of a feed-forward mechanisms between CLIC1 channel activity and ROS 
production.  
The fact that, in prolonged stress conditions, CLIC1 membrane expression becomes no more 
transient but chronic makes the channel a very interesting potential pharmacological target, 
making possible to hit specifically cancer cells. This will limit the toxicity due to the unspecific 
targets often choose in conventional antitumor therapies [26].  
   
2.3 Glioblastoma multiforme and cancer stem cells 
2.3.1 Gliomas  
Gliomas are the most common group of primary brain tumors characterized by high 
malignancy and invasiveness; each year, about 5–6 cases out of 100,000 people are 
diagnosed with primary malignant brain tumors, of which about 80% are malignant gliomas 
[56, 57]. These tumors took their name from the fact that they originates from neoplastic 
transformation of mature glial cells, especially astrocytes, oligodendrocytes or ependymal 
cells, or their precursors [58]. Gliomas include astrocytomas, oligodendrogliomas and 
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ependymomas. Malignant gliomas are subcategorized according to World Health 
Organization (WHO) into grade III tumors, such as anaplastic astrocytoma, anaplastic 
oligodendroglioma, anaplastic oligoastrocytoma and anaplastic ependymoma, as well as 
grade IV tumors, as glioblastoma multiforme (GBM), the most aggressive and lethal among 
the brain tumors. The WHO grade is assigned based on certain pathological features, such 
as nuclear atypia, mitotic activity, vascular proliferation, necrosis, proliferative potential, 
clinical course and treatment outcome [59]. Grade III and IV gliomas are characterized by 
necrosis and anaplastic cells that are able to hyper-proliferate and to infiltrate in the brain 
parenchyma.  Lower grade gliomas (I and II) are made of cells that are still differentiated, 
histologically similar to astrocytes and oligodendrocytes, they are mostly benign and with a 
better prognosis compared to higher grade gliomas [3, 60]. However, the fate of most low-
grade gliomas is to undergo malignant transformation over the years  
The diagnosis of brain tumors is performed by magnetic resonance imaging (MRI) and the 
use of adjunct technology such as functional MRI, diffusion-weighted imaging, diffusion 
tensor imaging, dynamic contrast-enhanced MRI, perfusion imaging, proton magnetic 
resonance spectroscopy and positron-emission tomography to define localization, 
dimensions and grade of the lesion. Anyway, it always has to be confirmed with a biopsy of 
the tumor mass. Clinically, patients with GBM may present with headaches, focal neurologic 
deficits, confusion, memory loss, personality changes or with seizures [61].  
The mean age for the diagnosis of gliomas is 64 years. Its incidence in the United States is 
estimated around 3:100,000 while more than 10,000 cases are diagnosed annually; 
incidence has increased slightly over the past 20 years, mostly due to improved radiologic 
diagnosis, and especially in elderly. This tumors are 1.5 times more common in men than 
women and 2 times more common in Caucasians compared to Afro- Americans [57].  
Nowadays, the gold standard of care in patients younger than 70 years old provides for 
maximal surgical resection plus radiotherapy plus concomitant and adjuvant temozolomide or 
carmustin administration. Unfortunately, despite the treatment, recurrence is likely to 
overcome and the great majority of the patients will die in two years from the diagnosis [56].  
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The biggest problems in the treatment of GBM are mainly the wide heterogeneity inter and 
intra-tumors, the high infiltration rate and the complexity for the therapeutic agents to cross 
the blood brain barrier and to hit selectively GBM cancer stem cells (CSCs), that are 
responsible for the tumor origin, progression and recurrence and that will be described 
deeply in the next paragraph.  
Concerning the genetic alteration of gliomas, there are some altered oncogenes and tumour-
suppressor genes involved in these pathologies. These mutations are not specific of brain 
tumors, however their combination and accumulation are characteristic. One of the earliest 
genetic modification in low-grade astrocytomas is the overexpression of platelet-derived 
growth factor (PDGF) ligands and receptors that cause an autocrine growth-factor stimulation 
loop and inactivation of the TP53 gene. Since the TP53 gene has several functions including 
to induce cell-cycle arrest (at the G1/S and G2/M transition points), DNA repair, apoptosis or 
their combination in response to genotoxic stress, its inactivation promotes abnormal cell 
division and seems to facilitate anaplastic transformation through genomic instability. In 
addition to TP53 mutation, the tumors have accumulated other genetic alterations, 
particularly those implicated in the retinoblastoma- mediated cell-cycle regulatory pathway 
eventually leading to an uncontrolled progression of the cell cycle from the G1 to the S 
phase. Moreover, a characteristic of primary malignant gliomas, especially glioblastomas, is 
amplification and overexpression of epidermal growth factor (EGF) receptor (>50% of cases).  
As for PDGF receptor, activation of EGF receptor induces downstream signal transduction 
pathways producing cellular proliferation and invasiveness. The retinoblastoma pathway is 
also altered in most primary malignant astrocytomas [60] [62]. Thus, gliomagenesis and 
tumor progression are closely associated with loss of cell cycle control and increased 
tyrosine-kinase signaling. At a late stage of tumor progression these pathways are involved 
in essentially all malignant gliomas and are linked together [60].  
In murine genetic models in which genes are introduced or removed at the germline 
(transgenic or knockout mice) or somatic levels (eg, gene transfer using retroviral vectors), 
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there is strong evidence of a causal role of the dysregulation of these pathways in glioma 
formation [3].  
Glioblastoma multiforme (GBM) is the most aggressive and lethal brain tumor; in the United 
States 54% of all gliomas are classified as GMB (Figure 4) and the median survival after the 
diagnosis varies from 6 months to 2 years; the five years survival rate is less than 3% [63]. 
Glioblastomas might develop de novo 
(primary glioblastoma) or through 
progression from low-grade or 
anaplastic astrocytomas (secondary 
glioblastoma). Primary GBMs account 
for a great majority of cases in older 
patients, while secondary GBMs are 
quite rare and tend to occur in 
patients below the age of 45 years. 
Primary GBMs present in an acute de novo manner with no evidence of prior symptoms or 
antecedent lower grade pathology. In contrast, secondary GBMs derive consistently from the 
progressive transformation of lower grade astrocytomas, with 70% of grade II gliomas 
transforming into grade III/IV disease within 5–10 years of diagnosis. Remarkably, despite 
their distinct clinical histories, primary and secondary GBMs are morphologically and 
clinically indistinguishable as reflected by an equally poor prognosis when adjusted for 
patient age. However, although these GBM subtypes achieve a common phenotypic 
endpoint, recent genomic profiles have revealed strikingly different transcriptional patterns 
and recurrent DNA copy number aberrations between primary and secondary GBM as well 
as new disease subclasses within each category [63].  
Initially it was considered that glioblastoma arose from astrocytic precursors and was 
genetically characterized by amplification of EGFR and expression of glial fibrillary acidic 
protein (GFAP). GFAP is highly specific for cells with astrocytic differentiation and is widely 
used as a reliable marker in immunohistochemical diagnosis and differentiation of brain 
Figure 4: frequency of primary CNS gliomas in the United States 
from 2004 to 2006[3] 
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tumors including glioblastoma [64]. In the last years however, many evidences have 
suggested that tumor organization could be described similarly to the hierarchy of stem cells 
and various progenitor cells that are locally restricted to the stem cell niche. Demonstrations 
that the adult human forebrain contains an abundant source of neural stem cells (NSCs) and 
that human GBMs contain tumorigenic neural stem-like cells indicate that neural stem and/or 
progenitor cells are a plausible origin for human gliomas and have given rise to speculations 
that more effective therapies will result from targeting stem cell-like component of GBMs [65, 
66].  
2.3.2 Brain tumor Cancer Stem Cells 
Historically, a stem cell is defined as an “undifferentiated cell capable of proliferation, self-
maintenance, production of a large number of differentiated functional progeny, regenerating 
the tissue after injury and flexible in the use of these options” [67]. Stem cells are 
undifferentiated cells able to generate every type of mature cells present in their tissue of 
origin (multipotency) and, at the same time, to maintain a constant pool of stem cells for the 
entire life of the individual (self-renewal) [1, 67]. Stem cells can accomplish self-renewal in 
two possible way; either undergoing asymmetrical divisions, by which are generated both a  
faithful copy of the mother cell  and a mature progenitor, or symmetrical division, by which 
are generated either two stem cells or two mature progenitors. The self-renewal capacity is 
the best feature to distinguish between somatic stem cells and their immediate descendants 
that are only able to reproduce themselves in a limited fashion. An alteration in the regulatory 
mechanisms that control self-renewal are probably involved in the genesis of cancer-initiating 
stem-like cells [1].  
The heterogeneity of tumor cells has long been appreciated, but only in 1997 a work from 
Dick’s laboratory described the isolation of a leukemia-initiating cell, the first purification of 
cancer stem-like cells, a population that had originally been proposed to exist  more than 150 
years earlier [68]. In the next years brain Cancer Stem Cells (CSCs) have been described in 
anaplastic astrocytoma, medulloblastoma, pilocytic astrocytoma, ependymoma, 
ganglioglioma and GBM [65, 69-71]. These brain CSCs have subsequently been shown to 
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be resistant to standard-of-care chemotherapy [72] and radiotherapy [73], underscoring their 
role in disease progression and recurrence.  
Regarding the origin of these CSCs there is evidence that multiple cell types, from stem cell 
to differentiated progeny, are amenable to oncogenic transformation. Therefore it is essential 
that the strictest functional assays continue to be performed. As the accepted functional 
definition of a stem cell is the ability to self-renew and generate differentiated progeny, also 
the cancer stem cells should be defined as a cell able of self-renewal, originating new 
malignant stem cells and, at the same time, capable to differentiate in every non-tumorigenic 
cell types present in the primary tumor [74]. CSCs are also described as a tumor 
subpopulation which can be self-renewed in vitro. Moreover, they are able to regenerate the 
tumor after orthotopic transplant in vivo and to originate all the tumor progeny both in vivo 
and in vitro [75]. As an examples, brain cancer stem cells have the ability to generate, upon 
intracranial transplantation, a tumor that recapitulates the cellular heterogeneity present in 
the parental tumor. 
Cancer arises from a series of mutations that occurs in few or even single founder cells, 
these cells eventually acquire unlimited and uncontrolled proliferation potential. This 
phenomenon could be 
explained by two hypothetical 
models: the stochastic or the 
hierarchical model (Figure 5). 
The first one predicts that all 
the cells in a tumor have a 
similar tumorigenic potential, 
activated asynchronously and at low frequency in certain cells. On the other hand, the 
hierarchical model claims that only a rare subset of cells within the tumor have significant 
proliferation capacity and the ability to generate new tumors, while the other bulk cells are 
differentiating or terminally differentiated cells. This second hypothesis fits with the cancer 
stem cell theory and, in the last years, is the most supported [1, 76]. Actually, it has to be 
Figure 5: stochastic and hierarchical models of tumors initiation and 
development [1] 
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pointed out that the CSC could be distinguished from the Tumor Initiating Cell (TIC), which is 
the first cell tumorigenically transformed and responsible for the origin of the tumor. As 
mentioned above, it has been recently demonstrated that a CSC do not necessarily derive 
from the transformation of a normal stem cell but it could originate from a more differentiated 
progenitor capable of self-renewing [74, 75, 77].  
Regarding brain tumors, the identification of the cellular origin of glioma is a great opportunity 
to improve the knowledge of the disease. Until the end of the 1990s there was the belief that, 
in an adult brain, mature glia was the only dividing cellular population and so that the 
neoplastic transformation of mature glia or the dedifferentiation of adult glial cells could be 
the only way for the gliomagenesis. In the last two decades a number of studies discovered 
and isolated other cellular populat ions in the brain able to proliferate, self-renew and 
originate neurons and mature glia after damage: neural stem cells and glial progenitor. The 
main implication of continued adult neurogenesis is the presence of these undifferentiated, 
mitotically active stem and progenitor cells within discrete regions of the mature brain. Like 
for the other tissues, these populations might function as a source of cells for transformation, 
giving rise to tumor stem cells [1].  
Neural stem cells can be isolated and expanded in cell culture depleted of serum and 
enriched with EGF (Epidermal Growth Factor) and FGF2 (Fibroblast Growth Factor 2). In this 
selective culture, partially differentiated cells died while neural stem cells rapidly divide in 
response to mitogen stimuli and form neurospheres in suspension that can be dissociated 
and re-plated to generate secondary spheres. The process can be repeated, resulting in a 
geometric expansion in the number of cells that are generated at each passage. Upon 
mitogen removal, the progeny of the proliferating precursor can be differentiated into 
neurons, astrocytes and oligodendrocytes, which are the three primary cell types found in 
adult mammalian central nervous system. This neurospheres assay allows to study the 
proliferative potential of stem cells populations and so is used to isolate, expand and identify 
neural stem cells, with multipotency and self-renewal ability [1].  
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The same assay is 
performed also to 
isolate, amplify and 
identify brain cancer 
stem cells (Figure 6). 
When these cells are 
plated in absence of 
mitogens they differentiate into the different cellular types that compose the tumor. With this 
assay, the presence of cancer stem cells is valuable only retrospectively; furthermore, if 
associated with in vivo tumorigenicity assays, it is used to confirm that the supposed cancer 
stem cell really is a tumor initiating cell [1, 78, 79]. 
Most glioma CSC markers have been appropriated from normal stem cells, but the link 
between glioma CSCs and normal stem cells remains controversial. Many of the transcription 
factors or structural proteins essential for normal neural stem cells function also mark glioma 
CSCs, including SOX2 [70], NANOG [80], OLIG2 [81], MYC [82], MUSASHI1, BMI1 [70], 
NESTIN [83] and inhibitor of differentiation protein 1 (ID1) [84]. However, because of the 
limited utility of intracellular proteins to enrich CSCs from non-stem tumor cells (NSTCs) 
using traditional methods such as flow cytometry, a multitude of potential cell surface 
markers have been suggested including CD133 [70], CD15 [85], integrin α6 [76], CD44 [86], 
L1CAM [87] and A2B5 [88]. These types of cell surface markers mediate interactions 
between cells and the microenvironment. Dissociation of cells from their surroundings rapidly 
degrades the informational content of markers, requiring rapid utilization.  
Although CD133 continues to be the most commonly used cell surface marker, other 
markers, such as integrin α6, have been proposed to segregate CSCs and NSTCs [89]. 
CD15/SSEA-1 and CD44 have also been proposed as possible markers, potentially in 
association with specific subgroups of GBM [90]. These markers are useful but they must be 
approached with caution. Each of them is able to interact with a large percentage of cells, 
consistent with a high false-positive rate. However it is likely that no marker will ever be 
Figure 6: Isolation and perpetuation of brain tumor stem cells in culture[1] 
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uniformly informative for CSCs: most tissue types contain multiple populations of stem cells 
expressing different markers and, in addition, for the inherent adaptability of cancer cells. 
Thus, several methods other than marker expression have been used to enrich glioma cell 
population with CSCs, such as the neurosphere assay. 
An alternative approach to CSC enrichment, which is based on the hypothesis that stem cells 
contain drug efflux transporters [91], is the use of flow cytometry to isolate a side population 
containing CSCs. While this approach has identified a population of self-renewing cells in a 
mouse glioma model, it has not been used successfully to enrich for self-renewing cells in 
human GBM [92, 93], highlighting the model- and species-specific challenges of enrichment 
methods. 
Therapeutically speaking, the 
discovery of brain cancer stem cells 
has two major implication: the 
cancer stem cells, which contain all 
the genetic information to faithfully 
reproduce the original tumor, can 
be used as a model to look for new 
diagnostic markers and for 
screenings of potential drugs; moreover, therapies directed specifically against CSCs could 
give better clinical outcomes (Figure 7). The great clinical challenge of GBM treatment is 
probably strictly connected to the existence of CSCs that are usually not the target of 
classical surgery or pharmacological treatments, which are normally directed against highly 
proliferating but not tumorigenic cells. CSCs, usually quiescent and with a high expression of 
anti-apoptotic proteins and drug efflux transporters are the reservoir for a potential tumor 
recurrence [1].  
 
 
Figure 7 : Comparison between conventional antitumoral therapy 
and a hypothetical therapy that hits specifically CSCs [2] 
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2.4 CLIC1 and glioblastoma 
An important role for CLIC1 as a chloride channel is specifically associated with the 
development of glioblastoma. CLIC1 is highly expressed in glioblastoma and both mRNA and 
protein levels are increased in high grade in comparison to low grade brain tumors or control 
(non-tumor) brain tissue [46, 54]. Upon CLIC1 silencing, both proliferative capacity and self-
renewal properties in vitro were impaired. Moreover, immunodeficient mice injected into the 
nucleus caudatus with CLIC1-silenced CSCs, survived longer than non-treated CSCs-
injected control mice [46]. However, RNA interference experiments per se are not able to 
distinguish whether CLIC1 is active as a cytoplasmic component or if the ability to modulate 
CSCs proliferation and migration is due to its plasma membrane ion channel property. To 
address this specific task, Setti and co-workers [46] showed not only that the IAA94-sensitive 
membrane current was drastically reduced in CLIC1 silenced human glioma CSCs, but also 
that CSC neurospheres, treated for 48 h with NH2-CLIC1 antibody, active as a CLIC1 
channel blocker only from outside the cell [32], compromised cancer development in injected 
mice. Angelini and colleagues [26] calculated the ratio between CLIC1-mediated current and 
other Cl− currents obtained from perforated-patch experiments in CSCs isolated from four 
different human glioblastoma postsurgical specimens. The relative large amount of CLIC1-
mediated current positively correlates with tumor aggressiveness. These results support the 
idea that the abundance of CLIC1 protein in the plasma membrane is a precise sign of a cell 
in unbalanced condition. This condition could be a transient event in a regular function of the 
cell life. However, if the protein overexpression becomes chronic as in glioblastoma CSCs, 
CLIC1 activity could be instrumental to the progress of the pathological state. More 
important, if the modulatory action is represented by the chloride ion channel, CLIC1 could 
be considered a privileged therapeutic target for CSCs in glioblastoma as well as in other 
untreatable tumors. A recent report from our laboratory strongly supported this hypothesis 
showing that CLIC1 activity can be pharmacologically regulated, discriminating among CSCs 
and normal stem cells. The inhibitory effect of both IAA94 and Metformin on proliferation was 
shown to be evident only in glioblastoma CSC-enriched cultures, while when the same 
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cultures were differentiated through a switch in the culture medium, they were unaffected. 
Moreover, in light of the proposed role of CLIC1 over-activation in glioblastoma cells , in 
differentiated cells, that are not sensitive to the antiproliferative effects of the membrane 
protein inhibition , CLIC1 was mainly confined to a cytosolic localization in an inactive form 
not reachable by the inhibitors [5]. These results strongly support the potential role of CLIC1 
as a pharmacological target that allows the discrimination between normal and tumor cells, 
especially in glioblastoma. In the same article, we reported also that the inhibition of CLIC1 
current leads to significant accumulation of CSCs in G1 phase of the cell cycle, suggesting a 
role for the channel in the progression of the cell cycle (Figure 8).  
 
Figure 8: effect of CLIC1 blockage with Metformin or IAA94 on the progression of cell cycle  [5] 
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2.5 pH and ROS in cell cycle progression and cancer  
2.5.1 pH  
Intracellular pH is fundamental for the activity of many enzymes, for the efficiency of 
contractile elements and for the conductivity of ion channels. Moreover, pH oscillations seem 
to be important in controlling the cell cycle and the proliferative capacity of cells. 
Regarding the enzymatic activity, an important example of pH sensitivity is 
phosphofructokinase, the rate-limiting enzyme of glycolysis, which activity increases with 
increasing pH in the physiological range [94]. Furthermore, protein, DNA and RNA synthesis 
are affected by internal pH levels; as an example, the pH optimum of DNA polymerases 
activity is generally quite high; it is reported to increase with increasing pH from 7.0 to 8.0 
[95].   
Thus, in general, the metabolic activities of cells raises with raising internal pH.  
Oscillations in intracellular pH have been shown to be important in the control of the cell 
cycle and cell division in both prokaryotic and eukaryotic cell type. A rapid increase in 
intracellular pH may be important to bring cells from G0/G1 into S phase [95].  
A work of Gerson and colleagues, showed a biphasic increase in pHi when lymphocytes 
were stimulated with the mitogen concanavalin A. The first peak was seen after 6-8 hours 
and the second peak 48 hours after the stimulation. While the first one correlated with early 
events, like the increase of phospholipids and protein synthesis, the second peak correlated 
with the synthesis of DNA [95].  
Several works reported different evidences about pH regulation of the cell cycle progression. 
One of the leading hypothesis is that, possibly, a pHi increase is necessary for the transition 
of cells from G0 to G1 in order to bring quiescent cells back into the cell cycle. Two works 
merged in this hypothesis; on one hand Pouyssegur reported that in response to growth 
factors, quiescent fibroblast mutants lacking the Na+/H+ exchanger activity failed to elevate 
their internal pH and to reinitiate DNA synthesis. On the other hand, Mills observed that 
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inducing proliferation in lymphocytes with interleukin 2 stimulates the Na+/H+ exchanger 
activity but if this exchanger was inhibited, proliferation occurred anyway [96] [97]. 
In the last decades it became more clear that maintaining a higher intracellular pH, 
associated with a more acidic extracellular space, is very important in the processes of 
neoplastic transformation and of tumoral progression. It seems that many typical features of 
a tumorigenic cells could derive from an alteration of the severe mechanisms that control 
internal pH. As an example, high cytoplasmatic pH could promote metabolic processes 
correlated with the cellular proliferation, while an extracellular acidification could increase the 
invasiveness of transformed cells [98] [99]. In this aberrant regulation of hydrogen ions 
dynamics an important role is played by the isoform 1 of the Na+/H+ exchanger, NHE. In 
cancer cells the NHE1 is hyperactive also in basal condition, leading to an alkalinization of 
the intracellular space that correlates with the uncontrolled proliferation typical of transformed 
cells [99]. It has been demonstrated that NHE1 has a role in in the regulation of the actin 
cytoskeleton dynamics necessary for the adhesion and pseudopodial protrusion of motile, 
invasive tumor cells [98]. 
The Na+/H+ exchanger is an antiport firstly identified in brush borders of rabbit kidney and 
small intestine [100]. It responds to a fall in extracellular pH by quickly extruding protons in 
exchange with extracellular Na+. The energy for the extrusion is provided by the large inward-
directed Na+ gradient [95]. The NHE is inhibited by the potassium-saving diuretic drug 
amiloride and its analogues. Amiloride inhibits the exchanger competitively binding to the 
extra-cellular site which accommodates Na+ ions. The antiport is also downregulated by the 
inhibition of the Na+/ K+ ATPase as well as the exposure of the cells to an external solution 
depleted of sodium [101] both action that dissipate the sodium gradient which drives the 
process. 
Amiloride is a less selective and more toxic inhibitor compared to more specific analogues 
like Cariporide or EIPA (ethylisopropylamiloride).  
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An accumulation of protons in the cytoplasm could act as an allosteric activator of the 
exchanger as well as the exposure to the compound FMLP (N-Formyl-L-methionyl-L-leucyl-
L-phenylalanine) [101].  
Usually, the activity of NHE is low and balances the passive H
+
 influx and the production of 
intracellular acidic metabolites; however, in specific condition, the activity of the exchanger 
could mediate a massive proton efflux, leading to an alkalinization of the intracellular 
compartment [95, 102].  
Oncogene-driven neoplastic transformation constitutively activates NHE1 and raises pHi by 
increasing the affinity of the allosteric proton regulatory site which mimics the lowering of 
cytosolic pH. Further, in a study to determine the mechanism of tumor cell activation by 
serum removal it has been demonstrated that this treatment stimulated NHE1 activity 
specifically in tumor cells though a PI3K-dependent increase of the affinity of this allosteric 
site.  
The activity of NHE1 in tumor cells has often been associated with the activity of bicarbonate 
transporting systems. The effect of this hyper activation can bring the cytoplasmic pH of 
cancer cells to values of 7,8. Interestingly, although in MCF-7 has been reported that both 
transporters contributed to regulate pHi, only the NHE1 played a role in regulating either 
motility or response to cisplatin chemotherapy [103].  
2.5.2 ROS 
Cellular proliferation encompasses tightly regulated biochemical and genetic pathways, the 
loss of which can lead to aberrant proliferation. In recent years, the role of the intracellular 
redox state as a growth regulator is increasingly becoming appreciated [104, 105]. Cellular 
redox state is a delicate balance between the levels of reactive oxygen species (ROS) 
produced during metabolism and the antioxidant system that scavenges them. ROS, 
including superoxide (O2·), hydrogen peroxide (H2O2) and hydroxyl radical (HO·) are known 
to inhibit activities of various biological molecules. However, at the end of the ‘90s , low 
levels of ROS have been recognized to serve as second messengers for signal transduction 
[106, 107].  
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In general, ROS contain one or more unpaired electrons in their highest occupied orbital. The 
partial reduction of molecular oxygen results in the production of superoxide (O 2·) and 
hydrogen peroxide (H2O2). O2· and H2O2 react with transition metal ions (e.g. cuprous and 
ferrous ions) through Fenton and Haber–Weiss chemistry, promoting further radical 
generation, including the highly reactive hydroxyl radical (HO·) [108].  
Cells can generate ROS from exogenous sources as well as endogenously. In the cytoplasm 
ROS are largely produced as oxidative by-products of cellular metabolism; mitochondria are 
the major site of O2· production. Other endogenous sources of ROS include the superoxide-
generating nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) oxidase 
complex, peroxisomes, metabolism of fatty acid chains, cytochrome P450 reductase, 
xanthine oxidase, myeloperoxidase and nitric oxide synthase [109-113]. 
To minimize the production of HO·, H2O2 levels are tightly controlled by several enzymes, 
including catalase, glutathione peroxidase, thioredoxin and peroxiredoxins. Cysteine, GSH, 
vitamins C and E (ascorbic acid and a-tocopherol), among others, constitute a pool of small 
molecular weight non-enzymatic antioxidants [106, 114-117]. 
As mentioned above, the cellular response to small changes in the ROS concentrations can 
have beneficial effects on cell growth and viability while higher concentration of these ROS 
caused toxicity and reduced cell number, so that, in the last decades, it has been delineated 
a biphasic effect of these compounds [118].  
Regarding cell cycle regulation, the first evidence of a redox cycle within the cell cycle came 
in 1931 from Rapkine [119] who demonstrated using sea urchin eggs the presence of soluble 
thiols that fluctuated cyclically. Later, Mauro et al., using synchronous HeLa cells, further 
dissected the changes occurring in protein-bound and non-protein sulfhydryl (–SH) and 
disulfide (–SS–) groups in each phase of the cell cycle [120]. Also budding yeast exhibits a 
metabolic redox cycle consisting of a reductive non-respiratory phase and an oxidative 
respiratory phase. Many of the genes regulating DNA replication and cell cycle progression 
are expressed during its reductive phase with cell cycle initiation occurring very late during 
the oxidative phase [121]. Menon and colleagues have shown previously that a transient 
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increase in prooxidant levels early in G1 is required for the cells to transit from G1 into the S 
phase, suggesting that an oxidative burst is required to proceed through G1 phase [55]. 
Moreover, reports from other laboratories have shown that sub–lethal doses of ROS (O2· and 
H2O2) added exogenously stimulated proliferation in cultured hamster fibroblasts [105, 122]. 
Observation by Conour et al. indicates GSH content was significantly higher in the G2/M 
phase compared to G1, suggesting that cells in the G2/M phase are at a more reduced state 
compared to the G1 phase. S-phase cells showed an intermediate redox state [123]. The 
hypothesis of a redox cycle regulating the cell cycle is also supported by reports of 
antioxidant enzymes influencing cellular growth stage [124]. Moreover, it has been reported a 
redox regulation of the cell-cycle–regulatory proteins that could be influenced by the 
presence of redox-sensitive motifs, such as cysteine residues or metal cofactors in kinases 
and phosphatases [125].  
This periodicity in intracellular redox state require a delicate balance between production of 
ROS and subsequent removal by antioxidants (both non-enzymatic and enzymatic 
pathways). Therefore, defects in ROS production and their removal could perturb the redox 
cycle, which in turn could lead to aberrant proliferation. Many of the proliferative disorders 
typical of pathophysiological conditions like cancer or neurodegeneration, are also 
associated with defects in the antioxidant pathways, presumably affecting redox regulation of 
cellular proliferation [126].  
Aberrant proliferation in cancer cells could be due to a loss in the redox regulation of the cell 
cycle. This was first reported by Oberley and Buettner[127] who showed that cancer cells 
exhibit lower levels of antioxidant enzyme activities compared with their respective normal 
cells, in particular MnSOD. Later on, other studies were published suggesting that oxidative 
stress could significantly contribute to cancer progression, possibly by perturbing the redox 
control of the cell cycle. Redox potential in normal cells correlates with Rb phosphorylation 
status during the cell cycle, proposing that perturbations in cellular redox potential could 
significantly affect the function of a tumor-suppressor gene [125]. Moreover, in response to 
the activation of many oncogenes (Ras, Raf, Myc, Bcr–Abl, ERB2, etc), the unconstrained 
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mitogenic signaling enhances the production of ROS. ROS and redox signaling have impacts 
on origin licensing, initiation of DNA synthesis, and/or replication fork travel, thereby inducing 
replication stress and the DNA-damage response, the mechanisms of this regulation still 
have to be fully elucidated [128].  
Furthermore, it is hypothesized that the metabolic redox-signaling pathways could initiate as 
well as promote carcinogenesis. This hypothesis is based on numerous studies 
demonstrating a regulatory role of MnSOD activity in cancer cell growth in both cell-culture 
and tumor xenograft animal model systems [125].  
 
2.6 pH regulation and ROS production in glioblastoma 
Malignant gliomas show an intracellular pH (pHi) more alkaline and an extracellular pH more 
acidic compared to non-transformed astrocytes, despite their increased protons production 
[129]. To maintain an optimal pHi, glial tumors must possess an efficient means of removing 
the excess H+ produced as a result of their increased metabolism. The first evidences about 
which were the principal mechanisms responsible for intracellular pH regulation in gliomas 
cell lines have been obtained in 1994 by Shrode and Putnam. They demonstrated that in C6 
rat glioma cell line the Na+/H+ exchanger NHE and the Cl-/HCO3- exchanger were active 
while the Na+/HCO3- cotransporter was absent [130]. 
Lately, McLean and colleagues demonstrated that three human glioma cell lines and one rat 
glioma cell line have an increased internal pH (0,3-0,5 unitis above pHi of normal astrocytes). 
Moreover they also demonstrated that these cells lines rely primarily on the Na+/H+ 
exchanger to maintain their alkaline pHi, whereas nontransformed astrocytes are able to 
maintain a constant pHi even in the absence of NHE activity. The elevated steady-state pHi of 
these glial tumors is not the result of genetic alterations of the NHE1 gene but is dependent 
upon an increased activity of this exchanger [131].  
NADPH oxidase, as previously told, is one of the sources of endogenous ROS production. It 
can exist in four different isoforms: NOX1, NOX2, NOX3 and NOX4.  
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Shono and colleagues a few years ago showed that gliomas prominently express Nox4 
transcript and protein and that the expression levels of Nox4 mRNA in GBMs (WHO grade 
IV) were significantly higher than those in other astrocytomas (WHO grade II and III). 
Moreover, in glioma cell lines the specific knockdown of this isoform leads to reduced 
expressions of some antiapoptotic genes and cell growth related genes and brings in 
morphological changes including a reduced cell size and multiple cytoplasmic processes 
[132].  
Some years later it has been demonstrated that Nox4 is essential for cycling hypoxia-
induced ROS production in GBM cells. Cycling hypoxia is a well-recognized phenomenon 
within animal and human solid tumors. It mediates tumor progression and radiotherapy 
resistance through mechanisms that involve reactive oxygen species production [133].  
The same laboratory, in a following study, demonstrated that the cycling hypoxic tumor cells 
derived from glioblastoma xenografts have much higher Nox4 expression, NADPH oxidase 
activity, ROS levels and radioresistance than chronic hypoxic cells or normoxic cells. 
Moreover, Nox4 blockade in intracerebral glioblastoma-bearing mice decreased tumor 
microenvironment induced Nox4 expression and radioresistance, and further increased the 
overall therapeutic efficiency of radiotherapy [134].  
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3.MATERIALS AND METHODS 
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3.1 Human Glioblastoma (GBM) Cancer Stem Cells (CSC) 
cultures 
GBM CSC cultures, already validated for CSCs properties and tumorigenicity, were kindly 
provided by Professor T. Florio’s laboratory, University of Genova.  
Post-surgical samples were used after patients’ informed consent and Institutional Ethical 
Committee (IEC) approval. All patients underwent surgery at Neurosurgery Department 
(IRCCS-AOU San Martino-IST) and had not received therapy prior to the intervention. 
Specimens were histologically classified as GBM grade IV (WHO classification).  
CSCs were grown at 37°C with 5% CO2 in stem cell-permissive medium composed of DMEM 
and F12-GlutaMAX 1:1, Penicillin/Streptomycin 1% and enriched with B27 supplement 1X, 
10ng/ml human bFGF and 20ng/ml human EGF. Cells were grown in suspension as 
spheroid aggregates (neurospheres) which formation occurred within 1 week of culture. 
Once a week neurospheres were mechanically dissociated into a single-cell suspension and 
re-plated in fresh medium to produce secondary neurospheres. In this way is possible to 
avoid the differentiation of cells in the center of the spheres that are losing contact with the 
selective medium.  
CSCs were also grown in the same medium as monolayer on growth factor-reduced Matrigel 
coating (BD Biosciences), allowing easier evaluation of viability, immunofluorescence or time 
lapse microscopy experiments without affecting stem cell features.  
3.1.1 G1 synchronization 
Monolayers cultures of CSCs have been synchronized in G1 phase of the cell cycle through 
36 to 60 hours of starvation in DMEM. Cells are released from the G1 blockage after the 
switch from DMEM to complete stem-cell permissive medium. For some experiments cells 
have been released in complete stem-cell permissive medium containing specific 
compounds (see “reagents”) 
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3.1.2 Transfection 
To monitor the oxidative stress, CSCs have been transfected with Cyto-roGFP2-VQ 
Ad5CMV K-NpA plasmid. This construct expresses the thiol redox-sensitive ratiometric 
sensor roGFP in the cytosol of mammalian cells. 
The cells have been transfected using Lipofectamine LTX and Reagent PLUS (Life 
Technologies), adapting the Invitrogen “Transfecting Primary Mouse Neural Progenitor Cells 
using Lipofectamine LTX reagent” protocol .  
To transfect 150000 cells, a mix of 6,25 μl of Reagent Plus and 2,5 μg of plasmid in 200 μl of 
DMEM is prepared. After 15 minutes at room temperature 3,75 μl of Lipofectamine LTX are 
added to the mix. The mix is left 30 more minutes at room temperature and then added to the 
CSCs culture which medium have been previously substituted with complete medium without 
antibiotics. The efficiency of the transfection is checked after 18-24 hours using a 
fluorescence microscope.  
 
3.2 Umbelical Cord Mesenchimal Stem Cells (uc-MSC) 
cultures 
uc-MSCs were kindly provided by Professor T. Florio’s laboratory, University of Genova. 
Human umbilical cords were obtained after caesarean section at Obstetrics and 
Gynaecology Department of International Evangelical Hospital (Genova, Italy), following 
informed consent and approval by IEC. After vessel removal, cords were treated with 
collagenase (0.5μg/ml) to expose Wharton jelly and obtain single cells.  
Cells were grown at 37°C with 5% CO2 in MesenPRO RS basal medium+Supplement (Life 
Technologies) after flow cytometry phenotypical characterization (MSC Phenotyping Kit, 
Miltenyi Biotec).  
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3.3 Reagents 
Indanyloxyacetic acid 94 (IAA94), (Sigma Aldrich), has been used to inhibit CLIC1 channel 
activity. Starting concentration: 50 mM in ethanol. 
Diphenyleneiodonium chloride (DPI), (Sigma Aldrich), has been used to inhibit NADPH 
oxidase activity. Starting concentration: 10 mM in DMSO. 
5-(N-Ethyl-N-isopropyl)amiloride (EIPA), (Sigma Aldrich), has been used to inhibit NHE1 
activity. Starting concentration: 50 mM in DMSO. 
N-Formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) (Sigma Aldrich), has been used to 
activate NHE1. Starting concentration: 1 mM in DMSO. 
 
3.4 Electrophysiology 
3.4.1 Patch clamp tecnique 
The patch clamp technique allows the measurement of the ionic currents passing through ion 
channels. It was developed by Neher and Sakmann in the late ‘70s  and it has brought great 
innovations in the fields of physiology and biophysics. In this technique a small heat-polished 
glass pipette is pressed against the cell membrane where the ion channels are embedded 
and forms an electrical seal with a resistance of ≈1-10 GΩ[135]. The high resistance of the 
seal ensures that most of the currents originating in a small patch of membrane flow into the 
pipette and, from there, into current measurement circuitry. An electrode (a silver wire coated 
with AgCl), located inside the glass pipette and connected to the circuitry, converts the ionic 
current into electrical current.  
From the cell-attached configuration described above other possible configurations are 
achievable (Figure 9): 
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- Inside-out configuration, 
where the pipette is rapidly 
withdrawed from the cell-
attached configuration without 
destroying the giga-seal, 
leaving a cell-free membrane 
and allowing current 
recordings in known 
intracellular solutions. 
- Whole cell configuration, 
where after giga-seal 
formation the membrane 
patch is disrupted providing a 
direct low resistance access to the cell interior allowing for recordings from the ion channels 
in the whole cell membrane.  
- Outside-out configuration, where the pipette is gently withdrawed from the whole-cell 
configuration without destroying the giga-seal, leaving a cell-free membrane patch exposing 
in the bath solution the outer leaflet of the lipid bilayer.  
- Perforated patch, where the pipette contains specific antibiotics (gramicidin, amphotericin 
B, nystatin..) that, once inserted in the plasma membrane of the seal, provide electrical 
access to the cell interior with the great advantage of preserving the cytoplasm content.  
3.4.2 Patch clamp experiments 
The patch electrodes (BB150F-8P with filament, Science Products) with a diameter of 1.5 
mm, were pulled from hard borosilicate glass on a Brown-Flaming P-87 puller (Sutter 
Instrument, Novato, CA) and fire-polished to a tip diameter of 1-1.5 µm and an electrical 
resistance of 3-4 MΩ. The cells were voltage-clamped using an Axopatch 200 B amplifier 
(Axon Instrument) in the perforated patch configuration. The antibiotic used is Gramicidin 
Figure 9: Patch clamp configurations  (from Encyclopedia of Biophysics- 
Patch-Clamp Recording of Single Channel Activity: Acquisition and 
Analysis Noel Wyn Davies) 
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(final concentration in the pipette 5 µg/ml) that forms pore in the membrane permeable only 
to monovalent cation; in this way the internal chloride concentration of the cells is preserved. 
Ionic currents were digitized at 5 kHz and filtered at 1 kHz. Clampex 8 was used as the 
interface acquisition program. The voltage protocol consisted of 800 ms pulses from -40 mV 
to + 60 mV (20 mV voltage steps). The holding potential was set according to the resting 
potential of the single cell (between -40 and -80 mV); a 15 ms prepulse of -40 mV is applied 
before starting the voltage steps, in this way the different recordings are comparable despite 
the different holding potential. 
CLIC1-mediated chloride currents were isolated from the other ionic currents in the cells by 
perfusing a specific inhibitor (Indanyloxyacetic acid 94; IAA94 100 µM) dissolved in the bath 
solution.  
The solutions used in the patch-clamp experiments of this thesis, referred to the article 
‘Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed 
astrocytes’[131], are the following: 
Bath solution (mM): 125 NaCl, 5.5 KCl, 24 HEPES, 1 MgCl2, 0.5 CaCl2, 5 D-glucose, 10 
NaOH, pH 7.4. 
Pipette solution (mM): 135 KCl, 10 HEPES, 10 NaCl, 1 MgCl2, pH 7,2. 
When required for the experiments EIPA 25 µM, DPI 10 µM and/or FMLP 100 nM are added 
directly in the bath solution starting from 15 minutes before the beginning of the experiments.  
3.4.3 Analysis 
Offline analysis was performed using Clampfit 10.2 (Molecular Devices) and OriginPro 9.1. 
CLIC1-mediated current (IAA94-sensitive current, IIAA94) was extimated by analytical 
subtraction of the residual ionic currents, after the addition of the inhibitor, from the total 
current (ITOT) of the cell at each membrane potential tested. Current/voltage relationships (I/V 
curves) were constructed plotting the averaged current density of the last 100 ms of the 
pulse against the corresponding membrane potential. Current density (pA/pF) results from 
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the ratio between the ionic current (pA) and the cell capacitance (pF). Error bars are the 
standard error of the mean in all plots. Statistical analysis were performed comparing the 
slopes (proportional to the channel conductance) of the I/V curves of the different groups. 
 
3.5 Protein extraction and Western Blot 
Cells samples (2*106  cells each) were collected by scraping directly with lysis buffer (LB; in 
water: 0.25 M Tris-HCl pH 6,8, 4% SDS, 20% Glycerol) or by centrifugation and 
resuspension in LB. Complete lysis of the cells was obtained by 10 minutes of incubation in 
LB at 95°C.  Concentration of protein lysates was assessed by BCA assay (Pierce). The 
same amount of proteins for each sample was loaded onto a 15% SDS-polyacrylamide gel 
electrophoresis (PAGE) under reducing conditions; before the loading 0.02% Bromophenol 
Blue and 2.5 %  β-mercaptoethanol were added to the samples; resolved proteins were 
transferred onto Nitrocellulose membranes (Protran) of 0,2 μm pore size into a transfer buffer 
(glycin 1%, tris-base 0,02 M, methanol 20%) to which is applied a constant voltage.  
Membranes were first incubated for 1 hour with 5% BSA in PBS-0,02% Tween to block non-
specific binding sites and then 1 hour with primary antibodies diluted in 5% BSA in PBS-
0,02% Tween. Antibody binding was assessed by horseradish peroxidase (HRP)-conjugated 
secondary antibody. Immunoreactive bands were detected with enhanced 
chemiluminescence reagents (ECL, Pierce).  
The antibodies used were the following: 
Purified Mouse Anti-Human Retinoblastoma Protein (BD Pharmingen) 1:1000 
Mouse monoclonal Anti-tubulin (Sigma) 1:5000 
Secondary anti-mouse antibody-HRP conjugated  (Sigma) 1:10000  
 
3.6 Immunofluorescence 
Indirect immunofluorescence was used to evaluate CLIC1 localization and P27 expression.  
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CSC’s monolayers of 5000 cells for each 12 mm diameter cover glass are washed with PBS 
Ca2+/Mg2+ and fixed with 2% paraformaldehyde in PBS Ca2+/Mg2+ for 10 minutes at room 
temperature. After some washing with PBS Ca2+/Mg2+ the samples are permeabilized with 
Bovine Serum Albumine (BSA) 5%-0,1% Triton X-100 in PBS Ca
2+
/Mg
2+ 
for 4 minutes and 
non-specific binding sites are blocked through a 30 minutes incubation with BSA 5 % in PBS 
Ca2+/Mg2+. Cells are washed twice with PBS Ca2+/Mg2+ and then incubated with the primary 
antibody diluted in PBS Ca2+/Mg2+ for two hours. After washes with PBS Ca2+/Mg2+ the 
samples are left for one hour in the dark with the secondary antibody diluted in PBS 
Ca2+/Mg2+, this antibody binds to the primary one and is conjugated with the fluorophore. To 
visualize cells nuclei the samples were treated 15 minutes with DAPI and then mounted on 
microscope slides using a glycerol-based mounting agent. 
Samples were observed under a confocal microscope Leica TCS SP2 with a Leica HCX PL 
APO 63X/1.4NA oil immersion objective for figures 10 and 20. To acquire images Leica 
confocal software was used. Laser lines 405 nm to see DAPI and 488 nm to see green 
fluorescence were used, the channels were acquired sequentially to avoid crosstalk 
problems. Samples were observed under a wide field Olympus  BX61 upright microscope 
with a CoolSnap Photometrics camera and 40X oil immersion objective for figure 13. To 
acquire images the Metamorph software was used. Excitation filters at 405 nm to see DAPI 
and 488 nm to see green fluorescence were used. Images were analyzed using ImageJ 
software. 
The antibodies used were the following:  
Mouse monoclonal anti-human CLIC1 (Santa-Cruz), 1:100 
Mouse monoclonal anti-P27 (Santa Cruz) 1:100  
Secondary antibody anti-mouse Alexa Fluor 488 (Life Technologies) 1:400 
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3.7 pH measurement 
Intracellular pH (pHi) is measured using the probe carboxy SNARF-1 AM (carboxy 
SemiNaphthoRhodaFluor acetoxymethyl ester – Life Technologies), calibrated with high 
potassium buffers and nigericin, following Chow and Hedley’s protocol [136]. The 
acetoxymethyl (AM) ester form of the dye enters the cells readily and is hydrolyzed by 
nonspecific cellular esterases to yield the free fluorescent dye. This pH probe is a weak acid 
with pKa values close to 7.0. Its protonated and free base forms, both excited at 514 nm, 
have different emission spectra (580 nm and 640 nm); taking the ratio of the two resulting 
emissions gives a signal that is proportional to internal pH and independent of cellular dye 
content. From the equation of a calibration curve, obtained using standards with known pHi, 
is possible to extrapolate the intracellular pH of the samples. 
Briefly, CSCs are dissociated, centrifuged for 10 minutes at 600 rpm and resuspended in 
PBS 1X (1*106cells/1 ml PBS). Each sample contains 5*105 cells in 500 μl of PBS. Carboxy 
SNARF-1 AM is added to each sample to a final concentration of 5 μM and cells are 
incubated for 30 minutes at 37°C in the dark. Samples are centrifuged at room temperature, 
resuspended in 500 μl of the desired solution and incubated for 20 minutes at room 
temperature in the dark: 
Samples: Sodium solution (125 NaCl, 5.5 KCl, 24 HEPES, 1 MgCl2, 0.5 CaCl2, 5 glucose, 10 
NaOH, pH 7.4) ± desired treatment  
Standards: high potassium buffers (pH 6.8-7.0-7.2-7.4-7.6-7.8) + nigericin (final 
concentration 2μg/ml) 
The standard solutions are obtained mixing 1:1 MES solution (mM: 140 KCl, 1 MgCl2, 2 
CaCl2, 5 D-glucosio, 20 MES) and TRIS solution (mM: 140 KCl, 1 MgCl2, 2 CaCl2, 5 D-
glucosio, 20 Tris base). Desired pH (6.8-7.0-7.2-7.4-7.6-7.8) is obtained adding an 
appropriate amount of the alkalinizing (TRIS) or acidifying (MES) solution to the starting 
solution. Nigericin allows exchange of H+ for K+ across their concentration gradients, so that 
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when external and internal potassium ion concentrations are approximately equal, there is 
free movement of hydrogen ions and intracellular pH is the same as extracellular pH.  
Samples are analyzed by flow cytometry with a FACS Aria (BD Bioscience) to determine the 
640/580 fluorescence ratio. 
The calibration curve, obtained with the values of the Em640/Em580 ratio of the standards, is 
built using Excel. 
 
3.8 ROS measurement 
To measure the redox conditions of the cells, CSCs were transfected with a plasmid carrying 
the sequence of Cyto-roGPF. Cyto-roGFP plasmid (ligated in the vector VQ Ad5CMV K-NpA) 
was a gift from Paul Schumacker (Addgene plasmid # 49435). This is a particular Ro-GFP 
genetically engineered to be express in the cytoplasm of the cells. This redox-sensitive 
protein emits at 525 nm and has excitation maxima at 400 and 484 nm. In response to 
changes in redox conditions, RoGFP exhibits reciprocal changes in intensity at the two 
excitation maxima [137]. Since the probe is ratiometric insensitive to its expression levels.  
Cells were transfected with the plasmid as described in the above section, seeded in 
adhesion on glass-bottom petri-dishes and the treatments added at the specific times (24 
hours or 30 minutes before the fluorescence acquisition). Cells expressing the roGFP2 redox 
sensor were then imaged in vivo by an inverted fluorescence microscope Nikon Ti-E (Nikon, 
JP) with a CFI Plan Apo VC 60X Oil objective. Excitation light was produced by a fluorescent 
lamp Prior Lumen 200 PRO (Prior Scientific, UK) switching between 470/40 nm and 405/40 
nm. Images were collected with a Hamamatsu Dual CCD Camera ORCA-D2 (Hamamatsu, 
Photonics, JP). The GRX-roGFP2 emissions were collected with a bandpass filter of 505-530 
nm for both excitation wavelengths. Exposure time was 100 ms with a 2x2 CCD binning for 
the 470/40 nm excitation, and 300 ms with a 2x2 CCD binning for the 405/40 nm excitation 
and images were acquired every 5 sec for 1 minute. Filters and dichroic mirror were 
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purchased from Chroma (Chroma Technology Corporation, USA). The NIS-Element (Nikon, 
JP) was used as platform to control microscope, illuminator, camera and post-acquisition 
analyses. Fluorescence intensities were determined over regions of interest (ROIs) 
(corresponding to the analyzed cells), background subtracted and used for the ratio (R) 
(405/488) calculation. The images analyzed using IMAGEJ software. 
 
3.9 Cell cycle analysis 
Cell cycle FACS analysis has been performed with a FACS Aria (BD Bioscience). Samples 
are analyzed at FACS using appropriate filter to visualize the fluorescence emitted by 
Propidium Iodide (PI) intercalated into the DNA (Em=488 nm; Ex=617 nm) to evaluate the 
DNA content. 
For each sample 2 millions of cells are washed with 500 μl of PBS 1X, centrifuged for 10 
minutes at 600 rpm and fixed with 1 ml of cold ethanol 70% in PBS. After at least two hours 
at 4°C, cells are centrifuged for 3 minutes at 2500 rpm and washed twice with PBS 1X to 
remove all the ethanol. After the last wash cells are resuspended in 200 μl of staining mix 
(Propidium Iodide 50 μg/ml, RNAsi 0,2 mg/ml, Triton X-100 0,5% in PBS 1X), incubated 30 
minutes at 37°C and directly read at the FACS.   
 
3.10 Viability assays 
Mitochondrial function, as index of cell viability, was evaluated by measuring the reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich). GBM 
CSCs were plated in 48-well matrigel-coated plates. The number of cultured cells was 
adjusted to a density that allowed the cells to grow exponentially for the full duration of the 
assay (up to 3 days) and thus ranged from 2,500 to 10,000 cells/well. After treatments, cells 
were incubated in MTT solution (2 mg/ml in PBS) for 2 hours, formazan crystals were 
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dissolved in DMSO, and absorbance was measured with a spectrophotometer at a 570 nm 
wavelength.  
 
3.11 Time lapse microscopy 
A ScanR Olympus system, with an inverted microscope IX81, a motorized Marzhauser’s 
stage and a Hamamatsu OrcaER camera, equipped with an OKOlab incubator to maintain 
samples at 37°C and with 5% CO2 was used to obtain time-lapse videos. 
CSCs are plated as monolayers in a 12-wells multiwell, 10000 cells for each well. To acquire 
the images each well is divided in 15 fields (5X3) and for each field images are taken with an 
Olympus 10X/0.30NA objective every 15 minutes for 24 hours. Excellence (Olympus) 
software has been used to acquire images. 
To edit the movies it has been employed Image J software 
 
3.12 Data elaboration and statistical analysis 
All the data that required statistical validation have been analyzed with the appropriate 
statistical test. 
The current density/voltage relationships of CLIC1 mediated current have been analyzed as 
following: for each condition every experiment has been plotted and the linear regression for 
the curve has been extrapolated (all significant, with R2≥0.9). A two-sample T-test, if the 
condition analyzed were only two, or a one-way ANOVA analysis  have been performed on 
the slopes of every experimental group. 
The western blot data are expressed as the intensity of the phosphorilated Rb band 
normalized on the intensity of the tubulin band. The experiment in figure 1 have been 
normalized on the value at 0 hours and the experiments in figure 3 on the value at 10 hours. 
A one sample T-test has been performed to validate the results for figure 3. 
46 
 
The data of the internal pH values have been expressed as the difference between the pHi of 
treated cells and the pHi of untreated cells (ΔpHi). Thus, an acidification will be indicated by a 
negative value while an alkalinization by a positive value. The results have been statistically 
analyzed using a one-sample T-test to confirm the difference from 0  for each group. 
 
  
47 
 
4.AIM OF THE THESIS 
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To propose and validate ion channels as new pharmacological targets it is fundamental a 
deep analysis of the levels and regulation of their activity during cancer cells proliferation.  
This thesis work aimed first of all to validate the specific function of CLIC1, in its 
transmembrane form, in GBM CSCs proliferation and cell cycle progression, proposing it as 
a specific target for GBM CSCs. 
Once confirmed the role of CLIC1 in the progression from G1 to S phase of the cell cycle, the 
second aim pursued was to evaluate if the activity of the channel was variable during the 
progression of G1 phase, in order to assign a specific timing to CLC1 membrane localization 
during the transition from G1 to S phase. 
The last purpose of this work was to study the regulation of CLIC1 channel activity in the 
progression of G1 phase of GBM CSCs by changes in internal pH and ROS levels. These 
two factors are known to oscillate during cell cycle progression and to be correlated in their 
dynamic mechanism. 
The general aim of this project is to elucidate the role of CLIC1, pHi and ROS levels in the 
cell cycle progression of GBM CSCs. We speculated a feed-forward mechanism, enrolling all 
these three elements, which sustains the proliferation of these cells. In this scenario CLIC1 
is, among the others, the most promising pharmacological target. The functional activity of 
CLIC1 as an ion channel is indeed specific of pathological conditions, compared to the 
systems that regulates pHi and ROS production that are constitutively active even during 
physiological state. Thus, to hit specifically CLIC1 channel will lower the chance of side 
effects of the therapy.  
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5.RESULTS  
  
50 
 
The experimental work done during my Graduate Studies can be summarized as follow: a 
systematic series of experiments to understand the mechanisms involving CLIC1 protein that 
sustain the repetitive cell cycle occurring in human glioblastoma cancer stem cells (CSCs) in 
culture. To accomplish my objectives I have used several different techniques depending on 
the different needs. The main achievement of this work is the dissection of the dynamic 
process underlying the cell cycle progression from G1 to S phase of CSCs. In this scenario 
CLIC1 protein appears to be an important as well as a peculiar player. Without its 
contribution CSCs lose the ability to maintain a high mitotic rate.       
5.1 Cell cycle progression in GBM CSCs 
The functional expression and activity of CLIC1 has been estimated during cell cycle of GBM 
CSCs to assess the timing of cell cycle progression in these cell cultures. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: confocal microscope images of p27 expression at different time points from the release from G1 
synchronization. The fluorescence associated with the protein clearly decreases at 10 and 12 hours after 
the release, indicating that the cells begin the transition from G1 to the S phase of the cell cycle. 
Indirect immunofluorescence on adherent GBM CSC has been performed to analyze the 
levels of p27, a CdK inhibitor protein which levels decrease during the progression from G1 
to S phase of the cell cycle. The cells have been synchronized in G1 phase, released from 
the arrest and the samples have been fixed at different times after the release (0, 4, 8, 10, 
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and 12 hours). At ten hours from the release the fluorescence associated with the levels of 
p27 expression decreases in intensity (Fig.10). To further confirm the time course of G1 
phase progression the levels of phosphorylated Retinoblastoma protein (Rb) have been 
evaluated through Western Blot analysis. Rb is a protein that, when phosphorylated, 
becomes inactive and allows cell cycle progression through S phase. The levels of 
phosphorylated Rb are dependent on p27 decrease.  
 
Figure 11: levels of phosphorilated Rb  (pRb) protein, normalized on tubulin, at 
different time points from the release from G1 synchronization. According with the 
data of p27 levels at 10 and 12 hours from the release pRb levels markedly increase. 
 
 
 
 
 
 
 
 
 
Figure 12: FACS analysis of cell cycle distribution (in%) of CSCs at different hours from the release 
from G1 synchronization. After 16 hours more than 30% f the cells analyzed were already in S 
phase, this percentage reached almost 60% after 20 hours. 
 
The quantification of the levels of phospo-Rb normalized with tubulin levels (n=3) showed a 
marked increase from 8 to 10 and then 12 hours from the release from G1 arrest (Fig.11). 
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These results were in accordance with the timing delineated by the previous experiment on 
p27 expression. 
To evaluate the time span of the transition to the S phase, we run a FACS analysis after PI 
staining at different time points after the release from G1 arrest of the cells. The times 
chosen were 0, 12, 14, 16, 18, 20 hours. At 16 hours after the release almost 30% of the 
cells were in the S phase (Fig.12). 
 
5.2 Effect of CLIC1 inhibition on CSCs cell cycle 
progression 
Once defined the timing of the transition of CSCs from G1 to S phase, we wanted to confirm 
the effect of CLIC1 inhibition on the cell cycle and on proliferation of these cells.  
We performed immunofluorescence analysis of p27 levels at 12 hours from the release of 
cells treated or not treated with 100 μM IAA94, the specific inhibitor of CLIC1 channel 
activity. The samples treated with IAA94 showed higher levels of p27 expression after 12 
hours from the release (Fig.13).  
 
Figure 13: wide-field microscope images of p27 protein expression at 12 hours from the release from G1 
synchronization in CSCs released in medium with or without IAA94 100 µM. The cells released in the 
medium containing the inhibitor at 12 hours showed still high levels of p27 protein.  
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To further confirm this evidence, we performed a western blot analysis of phosphorilated Rb 
levels on CSC treated or not treated with IAA94 at 10 hours from the release from G1 arrest. 
The samples treated with IAA94 showed a significant decrease in the levels of phospo-Rb 
compared to the controls (Fig.14). 
 
Figure 14: levels of phosphorilated Rb  (pRb) protein, normalized on tubulin, at 10 
hours from the release from G1 synchronization in medium with or without IAA94 100 
μM. The  cells released in IAA94 showed a significant decrease in the 
phosphorilation of Rb (n=3, One sample T-test, p<0,05) 
To observe the effect of CLIC1 inhibition on the percentage of cells progressed to S phase, 
FACS analysis has been carried out after PI staining of CSCs treated or not treated with 100 
μM IAA94 after the release from G1 arrest. The time points chosen were 0, 14, 16, 20 hours.. 
At 16 and 20 hours from the release a higher percentage of the cells treated with IAA94 was 
still in G1 phase compared to control condition (Fig.15). 
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Figure 15: FACS analysis of cell cycle distribution (in%) of CSCs at different hours from the release from 
G1 synchronization in medium with or without IAA94 100 μM. After both 16 and 20 hours from the release 
the percentage of cells still in G1 phase was higher in the samples treated with IAA94. 
 
 
Figure 16: Freeze frames of the videos 1 (CTRL) and 2 (IAA94) attached showing typical dividing times 
observed for the cells treated (B) or not treated (A) with 100 µM IAA94 in randomly growth conditions. The 
treatment with the inhib itor lead to a markedly slower dividing time 
 
Video microscopy is very useful to observe, in live condition, the effect of a particular cell 
treatment. In our case we recorded for 24 hours the behavior of GBM CSCs in the absence 
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or in the presence of the CLIC1 inhibitor IAA94. Particular attention was devoted to the cell 
division time. CSCs treated with IAA94 showed a lower rate of dividing cells and a longer 
dividing time (Videos 1 and 2, Fig.16).  
 
5.3 CLIC1 channel specificity in the proliferation CSCs 
It is important to evaluate the specificity of CLIC1 channel activity in the proliferation of CSC 
compared to other non-tumorigenic stem cells. For this purpose we performed MTT-viability 
assays on CSCs and umbilical cord mesenchymal stem cells (MSC) treated with different 
doses of IAA94 (n=3). CSCs viability was almost 50% when treated with IAA94 30 μM (IC50: 
32μM). On the contrary MSC weren’t affected by the treatment even at 100 µM suggesting 
that CLIC1 channel inhibition do not have any effect on the proliferation of these cells 
(Fig.17). 
 
Figure 17: Viab ility of CSCs and MSCs treated for 24 hours with different doses of IAA94 (n=3). For CSCs 
the EC50 of IAA94 was 32 µM while MSCs were not affected by the treatment even when the concentration 
reached 100 μM. On CSCs 30 µM IAA94 (One way ANOVA, Dunnet test p<0,01) and 100 μM (One way 
ANOVA, Dunnet test p<0,001) significantly decrease the growth of the cells compared to control 
conditions. 
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FACS analysis of cell cycle distribution on MSCs treated for 72 hours with IAA94 100 μM 
revealed the absence of effect of CLIC1 inhibition (Fig.18).  
 
Figure 18 FACS analysis of cell cycle distribution (in %) of MSCs treated (right) or not 
treated (left) for 72 hours with IAA94 100 μM. After the treatment there isn’t an increase in 
cells in G1 phase as observed for CSCs (Fig.8) 
 
Thus, to check if this missed effect of IAA94 on MSCs proliferation was associated with a 
lower amplitude of CLIC1 mediated chloride current compared to CSCs, we used an 
electrophysiological approach. Figure 19 reports patch-clamp experiments in the whole-cell 
perforated-patch configuration. In all the experiments carried out in our investigations CLIC1 
mediated current has been isolated by a mathematical subtraction using current recordings 
from control versus treated experiments (Fig.19). Steady state currents amplitude at the 
different membrane potential has been used to build a current/voltage relation showed in 
Figure 20. 
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Figure 19: representative current traces recorded from patch clamp experiments in whole cell perforated patch 
configuration, the protocol provides 6 steps of potential from -40 mV to +60 mV. On the left is depicted the current 
of the entire cell in control conditions, at the beginning of the experiment. In the trace in the middle there is the 
residual current after the inhibition of CLIC1 through the perfusion with IAA94 100 μM. The last current trace 
represents the current mediated by CLIC1 obtained from the subtraction of the current after IAA94 (middle) to the 
current at the beginning of the experiment (left). 
 
 
Figure20: current density/voltage relationships of CLIC1 mediated chloride current in 
MSCs (n=5) and CSCs (n=8). CSCs showed a significantly higher (Two sample T-
test, p<0.05) current compared to MSCs. 
The experiments performed showed that the medium CLIC1-mediated current density 
recorded in MSC is significantly lower than in CSCs. 
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5.4 CLC1 functional expression during cell cycle 
progression 
 
Figure 21: A. confocal microscope images of immunolocalization of CLIC1 in GBM CSCs at different time 
points from the release from G1 arrest. At 8 hours from the release there is a marked localization of the 
protein at membrane level. B. The freeze frames of the 3D reconstruction videos (Video 4 and 6)  of one 
cell at 4 hours (left) and one cell at 8 hours (right) from the release highlight the accumulation of CLIC1 in 
the plasma membrane at 8 hours 
Since the blockage of CLIC1 channel activity leads to an accumulation of CSCs in G1 phase, 
we verified whether CLIC1 membrane localization changes during G1 phase progression. To 
do this we performed an indirect immunolocalization for the protein on GBM CSCs fixed at 
different hours from the release from G1 arrest. In Figure 21 it is clear that the protein levels 
is high during all the time points but after 8 hours from the release there is a clear 
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accumulation of CLIC1 at the membrane level. The Z-stuck and the 3D reconstruction of the 
cell at this time point confirm the data (Fig.21 B, Videos 3-4 and 5-6).  
To confirm that this membrane localization was associated with the channel activity we 
repeated  perforated patch clamp electrophysiology experiments to monitor CLIC1 mediated 
chloride current at different hours from the release. Figure 22 compares IAA94 sensitive 
current amplitude obtained from synchronized cells at different time points from the release 
with data from randomly cycling CSCs. The increase of the current is evident between 4 and 
10 hours with a high value at 8 hours after the cells release. This in accordance with previous 
experiments demonstrating that CSCs are moving from G1 to S phase in the interval 
between 4 and 10 while at 18 hours cells have already progressed to S phase. 
 
Figure 22: current density/voltages relationships of CSCs at different times from the release from G1 
synchronization (4 hours n=5, 8h n=7, 10h n=5,  18h n=7) and randomly cycling (n=8). At 8 hours the increase in 
CLIC1 mediated current is significant compared to all the other conditions (One Way ANOVA, p<0.001 Tukey test 
vs randomly cycling cells and 18 hours, p<0.01 Tukey test vs 10 hours, p<0.01 Fisher test vs 4 hours). At 4 and 
10 hours the increase is still significant compared to randomly cycling cells and cells at 18 hours from the release 
(One Way ANOVA,  p< 0.001 compared with randomly cycling cells and 18 hours). Cells at 18 hours from the 
release showed a current superimposable to the current of randomly cycling ce lls. 
From this experiments it is possible to affirm that CLIC1 functional expression in the plasma 
membrane is maximum after 8 hours from CSCs release from synchronization. These data 
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are parallel with the result obtain with FACS analysis supporting the idea that CLIC1 chloride 
current is important for the cell cycle progression from G1 to S phase. In addition, current 
recordings at 18 hours showing a decrease of the current at the levels of control cells, 
strongly support the idea of a transient behavior of the IAA94 sensitive current. 
 
5.5 pH levels during cell cycle progression 
It is known that in artificial systems pH changes could influence CLIC1 membrane insertion 
[4]. Thus we wanted to verify whether pH oscillations, occurred during cell cycle progression 
of GBM CSCs, could influence CLIC1 activity. Using the SNARF1-AM dye we obtained a 
measure of the internal pH (pHi) with a cytofluorimetric analysis of CSCs from 3 to 12 hours 
after the release from G1 arrest (Fig.23). It is evident that between 8 and 10 hours from the 
release there is a peak in pHi levels. This time interval corresponds to the time at which 
CLIC1 membrane current increases (Fig. 22) supporting the idea of an interplay between pHi  
and CLIC1 functional expression as an ion channel in the plasma membrane.  
 
Figure 23: internal pH of GBM CSCs during G1 phase progression (from 3 to 12 hours after the 
release from G1 synchronization, n=3). Between 8 and 10 hours a peak in the pH i levels has 
been recorded. 
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5.6 pH regulation of CLIC1 channel activity 
 
Figure 24: A. internal pH values for GBM CSCs, the mean of 11 measuements was 
7.46. B. treatment with FMLP 100 nM (NHE1 activator) lead to a significant increase 
of pHi of  0.17  units (n=3, One sample T-test p<0.05); treatment with  EIPA 25 μM 
(NHE1 inhib itor) lead to a significant decrease of pH i of -0.19 units (n=4, One sample 
T-test p<0.05) 
It is known that glioblastoma cell lines have a higher internal pH compared to non-
transformed astrocytes and that pHi regulation relies mostly on the Na
+/H+ exchanger NHE1 
[131]. Using the SNARF1-AM dye we measured pHi of GBM CSCs culture randomly cycling. 
This procedure has been instrumental to study, in the short time range, the intimate relation 
between the pHi and CLIC1 protein functional expression. The modulation of the cytosol 
hydrogen ions content  can be achieved using two different compounds with opposite action. 
One inhibitor (EIPA, 25 µM) and one activator (FMLP, 100 nM) of the NHE1 have been 
evaluated. 
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The average pHi  of CSCs was 7.46; EIPA treatment leads to a significant decrease in pHi 
levels of about -0.19 pH unit. On the contrary FMLP treatment leads to a significant increase 
of internal pH of about 0.17 pH units (Fig.24). 
Since previously we observed a pH increase in the progression of G1 phase of CSCs cell 
cycle (Fig. 23), we checked if an induced alkalinization, using FMLP, could increase CLIC1 
membrane localization and channel activity. Figure 25 shows immunolocalization for CLIC1 
on CSCs treated for 30 minutes with 100 nM FMLP. The same treated cells were under 
electrophysiological investigation (Fig.26) to evaluate CLIC1 current density. Both 
experimental procedures confirmed that CLIC1 membrane localization increases and CLIC1 
mediated current is significantly augmented with cytosol alkalinization.  
 
Figure 25: confocal microscope images of immunolocalization of CLIC1 protein in CSCs 
treated or not treated with 100 nM FMLP for 30 minutes. The increased in pH i due to FMLP 
treatment leaded to a higher accumulation of the protein at the membrane level. 
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Figure 26: current density/voltage relationships for CLIC1 mediated current in CSCs 
pretreated (n=10) or not (n=8) with 100 nM FMLP. The increased in pH i due to FMLP 
treatment leaded to a significant increase (Two saple T-test, p<0,05) in the current that 
passes through CLIC1 
Since these experiments showed that higher pHi is able to increase CLIC1 channel 
activity, we decided to verify if preventing the increase in the internal pH during G1 
phase progression could counteract the increase of CLIC1 mediated current observed 
at 4 and 8 hours from the release from G1 arrest. We went back to perform 
electrophysiology experiments in perforated patch on GBM CSCs released from G1 
arrest in which we added in the medium 25 µM EIPA. Already at 4 hours but most at 8 
hours the treatment with EIPA and so the impossibility to increase pHi results 
associated with a significant decrease in CLIC1 mediated current (Fig.27).   
 
Figure 27: current density/voltage relationships of CLIC1 current in CSCs released from G1 arrest in medium with 
or without EIPA 25 μM to prevent the increase of pH i . Already at 4 hours from the release (left) (n=5, One way 
ANOVA, Fisher test p<0,05) but more clearly at 8 hours(right) (n=4, One way ANOVA, Tukey test p<0,001) the 
treatment with EIPA caused a significant decrease in the current compared to the corresponding untreated 
conditions. 
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5.7 Effect of CLIC1 current inhibition on pHi 
It is known that in activated microglia not only NADPH oxidase activity increases CLIC1 
mediated current but also that this chloride current sustains NADPH ROS production [45]. 
Therefore we verified if, with a similar feed-forward mechanism, the inhibition of CLIC1 
channel functional activity could have some effects on internal pH regulation. Thus we 
evaluated the internal pH using SNARF1-AM after treatment with IAA94 for 30 minutes and 
for 24 hours or after the co-treatment with IAA94 and EIPA for 30 minutes or IAA94 and 
FMLP for 24 hours (Fig.28).   
 
Figure 28: pHi measurement of CSCs treated with IAA94 100 μM. An acute 30’  treatment significantly 
alkalinized the cells (+ 0.23 units, n=3, One sample T-test p<0.05) , the alkalinization was counteracted 
by the co-treatment with EIPA 25 μM that brings the pH i to a more significant acidic level compared 
with the control (n=3, One sample T-test p<0.01). A chronic 24 h treatment significantly acidified the 
cells (-0.17 units, n=3, One sample T-test p<0.05)  and the effect was not counteracted by the co-
treatment with FMLP 100 nM (n=3). 
These experiments show that an acute IAA94 treatment leads to a significant increase in pHi 
of average 0.23 pH units that is completely counteracted by the co-treatment with EIPA, 
while a chronic CLIC1 inhibition leads to a significant acidification of average -0.17 units that 
is not recovered by the co-treatment with FMLP.  Starting from the effect of IAA94 observed 
on pHi, we performed preliminary trials with CSCs released from G1 synchronization in the 
medium containing 100 μM IAA94. Figure 29 shows the three most interesting time points, 
8,9 and 10 hours from the release. The treatment with the inhibitor decreases the pHi at all 
65 
 
the time points analyzed obstructing the increase of pHi observed between 8 and 10 hours 
from the release showed in the previous section (Fig.22).  
 
Figure 29: pHi of CSCs at 8,9 and 10 hours from the release from G1 synchronization 
in medium with or without IAA94 100 μM. When cells are treated with the inhib itor the 
increase in pH i is prevented. 
 
5.8 ROS regulation of CLIC1 channel activity 
Since is known that an increased NADPH oxidase (NOX) activity increases CLIC1 mediated 
current [45] and that an increase in ROS levels is also fundamental to progress from G1 to S 
phase of the cell cycle [138], we checked if the increase of CLIC1 mediate current observed 
at 4 and 8 hours from the release from G1 arrest was sensitive to NOX inhibition and so to 
ROS levels decrease. 
Thus, we performed perforated-patch electrophysiology experiments on GBM CSCs released 
from G1 arrest in a medium containing 10 μM DPI, a NOX inhibitor. Both at 4 and 8 hours 
from the release the CSCs released in the medium containing DPI showed a significant 
decrease in CLIC1-mediated current density compared to untreated cells at the same time 
points (Fig. 30). 
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Figure 30: current density/voltage relationships of CLIC1 current in CSCs released from G1 arrest in medium with 
or without DPI 10 μM to prevent the increase ROS levels . Both at 4 (n=6, One way ANOVA, Tukey test p<0,05) 
and 8 hours (n=5, One way ANOVA, Tukey test p<0,05)  the treatment with DPI caused a significant decrease in 
the current compared to untreated conditions. 
 
5.9 Effect of NADPH oxidase inhibition on pHi 
It is known that the internal pH and the ROS levels of the cells, especially related to NOX 
activity could influence each other [139, 140].  
To evaluate the effect of NADPH oxidase inhibition on the internal pH we measure hydrogen 
ion concentration using SNARF1-AM after the treatment with DPI 10 µM for 30 minutes or 24 
hours. In Figure 31 the experiment showed that both the treatments significantly decrease 
pHi, even if the acute treatment lead to a more evident result. In both cases the co-treatment 
with DPI 10 µM and FMLP 100 nM counteract this effect. 
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Figure 31: pHi measurement of CSCs treated with DPI 10 μM. An acute30’ treatment leaded to a strongly 
significant acidification (-0.24 units, One sample T-test p<0.001). A chronic 24 h treatment still significantly 
acidified the cells (-0.13 units, One sample T-test p<0.05). Both the effect were counteracted by the co-
treatment with FMLP 100 nM (n=3 for both) that brings the pH i to levels no more significantly different from 
the control. 
 
5.10 Recovery of CLIC1 activity after pH increase 
After we observed an effect on pHi when NOX activity was inhibited with DPI, we verified if 
the inhibition in CLIC1 current increase at 4 and 8 hours from the release from G1 arrest due 
to the DPI treatment could be, at least partially recovered by an induced pHi increase. Thus, 
the cells have been released in a medium containing both FMLP 100 nM and DPI 10 µM to 
increase the pH simultaneously with NOX inhibition (Fig.32). The experiments showed that 
the co-treatment with the two compounds leads to a partial, but significant recovery of the 
decrease in CLIC1-mediate current density both at 4 (n=7) and 8 (n=12) hours from the 
release. Infact, the current density/voltage relationships of CSCs released in DPI plus FMLP 
at 4 hours and 8 hours were no more significantly different from the corresponding untreated 
conditions.  
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Figure 32: current/voltage relationships of CLIC1 current in CSCs released from G1 arrest in medium with or 
without DPI 10 μM plus FMLP 100 nM to increase pHi while decreasing ROS production. Both at 4 (n=7) and 8 
hours (n=12) the simultaneous treatment with the two compounds leaded to the loss of significant difference in the 
amplitude of the current compared to untreated conditions. On the other hand, the currents of the cells treated 
with both compounds both at 4 and 8 hours returned to be significantly different from the randomly growing cells 
(4 hours: One way ANOVA, Tukey test, p<0,05; 8 hours: One way ANOVA, Tukey test, p<0,01)  
 
5.11 Effect of CLIC1 current inhibition on ROS levels 
To verify if, like in activated microglia [45], also in CSCs a feed-forward mechanism between 
CLIC1 current and NOX activity is present, we measured the oxidative levels of the cells. To 
do this it has been exploited the construct cytoRo-GFP that, as described in the methods 
section, is excited both at 405 and 488 nm and in response to changes in redox conditions 
exhibits reciprocal changes in intensity at the two excitation maxima. Since in the literature 
there are no data about the use of this probes in primary cell cultures, the optimal conditions 
for the transfection of the cells with the plasmid and for the performance of the experiments 
have been defined after some trials.  
The first experiments performed have been carried out on CSCs transfected with the plasmid 
and treated with IAA94 100 µM for 30 minutes and 24 hours. 
Unfortunately the samples treated for 30 minutes in the first two trials gave not congruent 
results. On the other hand, the cells treated for 24 hours with the inhibitor showed a 
decrease in the oxidative status compared with the control (n=2) (Fig.33). This is a promising 
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result that will be confirmed with more trials in which the experimental conditions will be even 
more optimized.  
 
Figure 33: ROS levels evaluation in CSCs treated for 24 hours with IAA94 100 µM. The results are 
normalized on the level of the ratio Ex405/Ex488 of the cells in control conditions. The treatment with 
IAA94 lead to a decrease (n=20) in the oxidative levels of the cells. 
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6. DISCUSSION 
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Allostasis, in the living organisms, is defined as the process of achieving a new state of 
transient stability through physiological or behavioral changes. Allostasis is essential in order 
to maintain internal viability during changing conditions. When allostasis become chronic, 
due to constant stress exposure or due to the failure of the cell systems to restore the 
homeostatic conditions, it causes a situation of allostatic overload that might lead to 
pathological conditions. The concept of allostasis envisions a cascade of causes and effects 
that begins with primary stress, leads to primary modulation and then to secondary and 
maybe tertiary outcomes, until a new equilibrium arises [141, 142]. Allostasis and allostatic 
overload can be applied to biological entities from ensemble of organs, functional systems, 
tissues and also to single cells. 
The general hypothesis sustaining this thesis work concerns the concept that during 
gliomagenesis a restrict number of neural stem cells and/or mature glial cells reaches a new 
steady state going from resting-cells homeostasis to the allostatic condition of cancer stem 
cells (CSCs). From our point of view the majority of the proteins present on CSCs plasma 
membrane is either upregulated or depressed in their quantity and/or function. In GBM cells 
ionic channels [46, 143] , transporters [144], proton pumps [145], membrane receptors [146] 
and also pro-oxidative mechanisms [132] have been previously described to be 
overexpressed, not present, hyper-activated or down regulated compared to control 
conditions. In this chronic allostatic system, a modification of any of these proteins produces 
a disruption of the new equilibrium and eventually results in the cell death. What is 
particularly problematic is that all the known proteins that are dysregulated in the tumorigenic 
process are also protein with important physiological roles in the homeostatic situation as 
well. Thus, if it is true that by hitting for example one of the overexpressed elements it may 
be possible to destroy the cancer stem cells, it is also realistic that healthy cells will be 
damaged by the same procedure. The idea, to design a successful therapy, is to identify 
proteins not only fundamental but also specific for the tumorigenic processes typical of 
CSCs. An unambiguous target will allow, once modulated, to impair only tumor cells avoiding 
serious collateral damages. 
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The experiments carried out in this thesis confirm that CLIC1 could be a valid candidate to 
match this specificity. 
It has been shown that CLIC1 is functionally active and fundamental in the proliferation 
process of CSCs but not of MSCs (Figure 17). Moreover the channel activity inhibition 
obtained by the specific inhibitor IAA94 lead to accumulation of CSCs in G1 phase  
suggesting the need of CLIC1 mediated chloride current for the transition from G1 to S phase 
of the cell cycle (Figure 15). 
Through immunolocalization of the protein and electrophysiological measurement of the 
chloride current we identified a precise timing in which CLIC1 accumulates at the membrane 
level. In CSCs CLIC1 activity reaches a maximum during the progression of G1 phase.  
When cells are synchronized in G1 and released, the current mediated by CLIC1 markedly 
increases and reaches a peak of amplitude around 8 hours later (Figure 21-22). At 18 hours 
from the release, when many of the cells are already progressed to S phase, the current 
significantly decreases and becomes comparable to the average current of randomly cycling 
cells (Figure 22). The fact that the randomly cycling cells show an average current density 
that is significantly lower compared to the current at 8 hours from the release suggests that 
the timing of the increase of the current is tightly regulated and that it happens in a very 
narrow time slot.  
The literature proposes two principal factors regulating CLIC1 membrane insertion and 
channel activity: pH and ROS [4, 6, 7, 28, 45]. The thesis experimental work demonstrates 
that inducing CSCs cytoplasm alkalinization lead to an increase in the current mediated by 
CLIC1 (Figure 25-26).  It is known that cancer cells display a high internal pH and there are 
some evidences for an oscillation of pHi during cell cycle progression [95, 131]. We now 
found that in CSCs released from G1 arrest the pHi peaks between 8 and 10 hours after the 
release reaching almost a value of 8 (Figure 23). This corresponds to the time in which 
CLIC1 chloride current results augmented.  
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The suggested regulation of CLIC1 activity by pHi during cell cycle progression is confirmed 
by the inhibition of Na+/H+ exchanger 1 (NHE1). Releasing the cells in a medium containing 
EIPA, a specific NHE1 inhibitor, CLIC1 current increase is abolished both at 4 and 8 hours 
from the synchronization release (Figure 27). NHE1 is the exchanger responsible for most of 
the internal pH regulation in glioblastomas cells; an inhibition of NHE1 using EIPA will lead to 
acidification while an activation using FMLP will have the opposite effect (Figure 24). Thus, 
the increase in CLIC1 activity during the progression of G1 phase is related to an increased 
NHE1 activity. 
The other factor known to regulate CLIC1 activity is the oxidative level of the cells. It has also 
been demonstrated that an increase in ROS level is fundamental for the progression from G1 
to S phase of the cell cycle [55, 138] and that in glioblastoma cells the isoform 4 of NADPH 
oxidase (NOX) is overexpressed [132]. In addition, our data showed that ROS production  is 
implicated also in the regulation of CLIC1 current observed during G1 progression. Indeed, 
when we release the cells after G1 synchronization in a medium containing the NOX inhibitor 
DPI, we were unable to record a significant increase of the current both at 4 and 8 hours 
from the release (Figure 30).  
All the data we presented so far confirm CLIC1 involvement in the progression of the cell 
cycle and pave the way for uncovering the mechanism involved in the modulation of the 
channel activity. There are two important questions that are legitimate to ask:  
a. Are the three elements equally influenced by the other two in case of a specific 
inhibitory action? 
b. Considering only the three player during the progression of the cell cycle, is one of 
them responsible for the beginning of the process that moves the cells from the homeostatic 
to the allostatic conditions? 
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These questions are very important. Knowing the “on” mechanism it will be also possible to 
study the “off” process and in this way understanding the relations between the three 
components.   
In a previous investigation involving the activation of microglia cells during infection of the 
central nervous system our laboratory described a positive feed-forward mechanism between 
ROS production and CLIC1 functional expression as an ion channel in the microglia cells 
membranes [45] 
Activated microglia is an allostatic system in which all the three elements (CLIC1, NHE1 and 
NOX) are hyper-active and influence each other activity. When microglia is activated there is 
an increase in ROS levels. This increase is related to an augmented assembly on the 
membrane and a higher activity of NADPH oxidase [147]. From the literature about CLIC1 it 
is also known that this increased activity of NOX is associated with an increased activity of 
the channel [44, 45]. Moreover, as described in the introduction, it has been demonstrated 
that CLIC1 and NOX in activated microglia are part of a feed-forward mechanism. The 
NADPH oxidase by synthetizing ROS produces also an outward negative charge flow that 
need to be compensated. In this case it is required either a positive charge outflow or an 
inward movement of negative charges. Among all the possibilities represented mainly by 
potassium ions, CLIC1 has been identified in this contest to play a major role. In microglia 
cells activated by Aβ as an example, CLIC1 moves to the membrane where it forms an ion 
channel that mediates a chloride current  necessary to support NOX activity [45]. Activated 
microglia and glioblastoma cells share also common mechanisms in the regulation of internal 
pH; NHE1 plays a key role in maintaining resting pHi both in glioblastoma and in microglia 
cells [131, 139].  
Moreover the activation of microglia is associated with an alkalinization of the cytoplasm due 
to an augmented NHE1 activity. This increased activity of NHE1 is stimulated by the increase 
in the activity of NOX since when the cells are treated with DPI the activation of the 
exchanger is reduced by 50% [139]. pH changes and ROS production have been proposed 
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to participate to a feed forward mechanism since the activity of NHE1 in the extrusion of H+ 
produced by NADPH oxidase is fundamental to maintain the optimal pHi necessary for the 
activity of the enzyme. When NHE1 is inhibited in activated microglia NOX activity is reduced 
[139].  
All these similarities suggest for the presence of comparable mechanisms of mutual-support 
of the activities of CLIC1, NHE1 and NOX also in glioblastoma CSCs.  
Our experiments prove that both the inhibition of CLIC1 current and NOX impair the pHi 
regulation by NHE1. When NADPH oxidase is inhibited by DPI treatment both during an 
acute (30 minutes) and chronic (24 hours) treatment, pHi decreases (Figure 31). Acidification 
is recovered if the DPI treatment is associated with an activation of NHE1 by FMLP 
confirming the regulation of NHE1 functioning by NOX (Figure 31). This is observed also in 
the regulation of CLIC1 current during cell cycle progression. The decrease of CLIC1 current 
at 8 hours from the release from G1 synchronization, that is observed when NADPH oxidase 
is inhibited, is partially recovered by the simultaneous activation of NHE1; these data suggest 
a double effect of NADPH oxidase on CLIC1 activity: one direct and one indirect through 
NHE1 (Figure 32). 
The scenario of the effect of  CLIC1 inhibitor IAA94 treatment on NHE1 is more complex. An 
acute treatment of 30 minutes leads to a hyper-activation of NHE1, recorded as an 
alkalinization that is counteracted by the co-treatment with the NHE1 inhibitor EIPA. On the 
other hand, a long treatment of 24 hours acidifies the cytosol of CSCs and the effect is not 
recovered by the treatment with FMLP (Figure 28). Moreover, the increase of pHi observed 
during the progression of G1 phase seems to be limited when CLIC1 is inhibited by IAA94 
treatment (Figure 29). We can speculate that this opposite effect could be due to an 
immediate compensative hyper-activation of NHE1 after CLIC1 inhibition that in the long run 
is progressively extinguished, since the channel activity is necessary to sustain the 
exchanger, leading to the opposite effect of acidification.  
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The first experiments to monitor the oxidative levels of the cells suggest an effect of IAA94 
on ROS production (Figure 33). This could be interpreted as a CLIC1 current support of 
NADPH activity. These last experiments need to be confirmed and the effect of the short 
treatment with IAA94 need to be clarified. In the nearest future plan there is also the 
demonstration of an effect of NHE1 inhibition on the oxidative levels of CSCs as suggested 
from the literature and from all the other results obtained until now. This will in a way “close 
the circle” and shed light on the possibility that one of the three elements involved in this loop 
could be the trigger for its activation.  
However, all the experiments presented in this thesis clearly confirm that in the allostatic 
system represented by CSCs there is a functional loop between the NHE1 exchanger, CLIC1 
and the membrane NADPH oxidase, all of them overexpressed and upregulated in CSCs. 
During G1 phase progression the exchanger increases the cytoplasm pH, favoring CLIC1 
channel activity. The increase in ROS levels through the activation of NADPH oxidase 
stimulates CLIC1 membrane insertion and sustains NHE1 activity. CLIC1 ionic current 
supports the work of both NADPH oxidase in the production of superoxide and NHE1 in the 
H+ extrusion. In this scenario, all of these membrane proteins participate to the 
gliomagenesis sustaining CSCs cell cycle progression. To hamper this mechanism it is 
possible to act on each of the components. However, while NHE1 and NADPH oxidase are 
essential for brain cells homeostasis, CLIC1 chloride channels are present in the membrane 
exclusively in glioblastoma allostatic system making the channel protein the most attractive 
pharmacological target. 
The parallel with the allostatic system of activated microglia, in which CLIC1, NHE1 and 
NADPH oxidase are all hyper-active and influence each other activity, besides sustaining our 
hypothesis, gives the possibility to study the interaction between the three elements in a 
system that is inducible. This could be of great help in defining the exact timing of the hyper-
activation of every single factor and the influence of this activation on the activity of the 
others. 
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